U.S. patent application number 14/785047 was filed with the patent office on 2016-04-07 for bioresorbable biopolymer anastomosis devices.
This patent application is currently assigned to Trustees of Tufts College. The applicant listed for this patent is BETH ISTAEL DEACONESS MEDICAL CENTER, INC., TRUSTEES OF TUFTS COLLEGE. Invention is credited to Abdurrahman Abdurrob, Ahmed Ibrahim, Rodrigo R. Jose, David L. Kaplan, Samuel Lin, Waseem K. Raja.
Application Number | 20160095599 14/785047 |
Document ID | / |
Family ID | 51792513 |
Filed Date | 2016-04-07 |
United States Patent
Application |
20160095599 |
Kind Code |
A1 |
Jose; Rodrigo R. ; et
al. |
April 7, 2016 |
BIORESORBABLE BIOPOLYMER ANASTOMOSIS DEVICES
Abstract
A bioresorbable drug-eluting biopolymer suture-free blood vessel
anastomosis devices can be deployed to join two blood vessels and
resorbed by the body over a predetermined time period after the
blood vessel has become joined. The anastomosis device can include
a hollow tube that is inserted interconnect the two vessels to be
jointed. A non-piercing suture is wrapped around the vessel to
secure the anastomosis. The anastomosis device can include hollow
tube that extends along an axis from a first end to a second end.
The ends can be fitted with elements that facilitate mechanical
attachment of the vessel to the anastomosis device and provide for
a secure seal.
Inventors: |
Jose; Rodrigo R.; (Medford,
MA) ; Raja; Waseem K.; (Medford, MA) ; Kaplan;
David L.; (Concord, MA) ; Ibrahim; Ahmed;
(Brookline, MA) ; Lin; Samuel; (Dover, MA)
; Abdurrob; Abdurrahman; (Winchester, MA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
TRUSTEES OF TUFTS COLLEGE
BETH ISTAEL DEACONESS MEDICAL CENTER, INC. |
Medford
Boston |
MA
MA |
US
US |
|
|
Assignee: |
Trustees of Tufts College
Medford
MA
Beth Israel Deaconess Medical Center, Inc.
Boston
MA
|
Family ID: |
51792513 |
Appl. No.: |
14/785047 |
Filed: |
April 24, 2014 |
PCT Filed: |
April 24, 2014 |
PCT NO: |
PCT/US14/35361 |
371 Date: |
October 16, 2015 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
61815551 |
Apr 24, 2013 |
|
|
|
Current U.S.
Class: |
606/154 |
Current CPC
Class: |
A61B 2017/00893
20130101; A61B 2017/00004 20130101; A61L 27/502 20130101; A61B
2017/00858 20130101; A61B 2017/1107 20130101; A61B 2017/00526
20130101; A61L 27/507 20130101; A61B 2017/00778 20130101; A61B
2017/1132 20130101; A61B 17/11 20130101 |
International
Class: |
A61B 17/11 20060101
A61B017/11 |
Goverment Interests
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH
[0002] This invention was made with government support under grant
EB002520 and 3 P41 EB002520-09S1 awarded by the National Institutes
of Health. The government has certain rights in the invention.
Claims
1. A biopolymer anastomosis device for connecting a first blood
vessel to a second blood vessel, the biopolymer anastomosis device
comprising: a hollow tube extending along a longitudinal axis from
a first end to a second end, the outside diameter of the hollow
tube at the first end being larger than the inside diameter of the
first blood vessel and adapted to be inserted into the first blood
vessel, and the outside diameter of the hollow tube at the second
end being larger than the inside diameter of the second blood
vessel and adapted to be inserted into the second blood vessel; and
wherein the hollow tube is formed of a blend that includes silk
fibroin and a plasticizer.
2. The biopolymer anastomosis device according to claim 1 wherein
at least one of the first end and the second end is enlarged such
that the outside diameter is substantially larger than the inside
diameter of the blood vessel to be fit over the end of the hollow
tube.
3. The biopolymer anastomosis device according to claim 2 wherein
the wherein at least one of the first end and the second end has an
outside diameter that is at least 125% of the inside diameter of
the blood vessel to be fit over the end of the hollow tube.
4. The biopolymer anastomosis device according to claims 1-3
further comprising a non-piercing suture wrapped around at least
one of the first blood vessel and the second blood vessel to secure
it to the hollow tube.
5. The biopolymer anastomosis device according to claim 5 wherein
the non-piercing suture is formed from a material including
dextrose rods and HFIP solubilized silk fibroin.
6. The biopolymer anastomosis device according to claim 5 wherein
the non-piercing suture is formed from a material including
fine-drawn dextrose rods coated with HFIP solubilized silk
fibroin.
7. The biopolymer anastomosis device according to claim 1 wherein
the first end includes a first spherical enlarged portion and the
second end include a second spherical enlarged portion and the
biopolymer anastomosis device further comprises a first threaded
sleeve adapted to be screwed onto the first spherical enlarged
portion after the first spherical enlarged portion is inserted into
the first blood vessel.
8. The biopolymer anastomosis device according to claim 7 further
comprises a second threaded sleeve adapted to be screwed onto the
second spherical enlarged portion after the second spherical
enlarged portion is inserted into the second blood vessel.
9. The biopolymer anastomosis device according to claim 8 wherein
the second threaded sleeve is adapted to fit over the first
threaded sleeve.
10. The biopolymer anastomosis device according to claim 1 wherein
the first end includes at least one barb extending substantially
transverse to the longitudinal axis of the hollow tube and adapted
to penetrate at least a portion of the first blood vessel; and
further comprising a first sleeve adapted to fit over the first
blood vessel when the first blood vessel is fitted over the first
end of the hollow tube and penetrated by the at least one barb to
capture the first blood vessel between the first end and the first
sleeve.
11. The biopolymer anastomosis device according to claim 10 wherein
the first end includes a plurality of barbs that are arranged
around the first end.
12. The biopolymer anastomosis device according to claim 10 wherein
the at least one barb is a microneedle.
13. The biopolymer anastomosis device according to claim 10 wherein
the first end includes a plurality of microneedles that are
arranged around the first end.
14. The biopolymer anastomosis device according to claim 10 wherein
the second end includes at least one barb extending substantially
transverse to the longitudinal axis of the hollow tube and is
adapted to penetrate at least a portion of the second blood vessel;
and further comprising a second sleeve adapted to fit over the
second blood vessel when the second blood vessel is fitted over the
second end of the hollow tube and penetrated by the at least one
barb to capture the second blood vessel between the second end and
the second sleeve.
15. The biopolymer anastomosis device according to any of claims
1-14, wherein the blend comprising silk fibroin and plasticizer
further comprises an additive.
16. The biopolymer anastomosis device according to claim 15,
wherein the additive is selected from the group consisting of
anti-proliferative agents, biopolymers, nanoparticles (e.g., gold
nanoparticles), proteins, peptides, nucleic acids (e.g., DNA, RNA,
siRNA, modRNA), nucleic acid analogs, nucleotides,
oligonucleotides, peptide nucleic acids (PNA), aptamers, antibodies
or fragments or portions thereof (e.g., paratopes or
complementarity-determining regions), antigens or epitopes,
hormones, hormone antagonists, growth factors or recombinant growth
factors and fragments and variants thereof, cell attachment
mediators (such as RGD), cytokines, enzymes, small molecules,
antibiotics or antimicrobial compounds, toxins, therapeutic agents
and prodrugs, small molecules and any combinations thereof.
17. The biopolymer anastomosis device according to any of claims
1-16, wherein the cylindrical body portion is a multilayered
cylindrical body portion.
18. The biopolymer anastomosis device according to claim 17,
wherein a first layer and a second layer of the cylindrical body
portion each comprise at least one additive.
19. The biopolymer anastomosis device according to any of claims
15-18, wherein degradation of the blend material or optional
release of the additive from the blend material varies with the
beta sheet content of silk fibroin in the blend material.
20. The biopolymer anastomosis device according to any of claims
1-19, wherein the cylindrical body portion has an average
mechanical stiffness of 1.2 kN/m.
21. The biopolymer anastomosis device according to any of claims
1-20, wherein the cylindrical body portion has an average radial
strength of 300 mmHg.
22. The biopolymer anastomosis device according to any of claims
1-21, wherein the blend material comprises micropores.
23. The biopolymer anastomosis device according to claim 22,
wherein the anastomosis device functions as an endovascular stent
graft to prevent the rupturing of weakened blood vessel walls.
24. The biopolymer anastomosis device according to any of claims
1-23, wherein the blend comprising silk fibroin and plasticizer
further comprises an active agent.
25. The biopolymer anastomosis device according to claim 24,
wherein the active agent is a therapeutic agent.
26. The biopolymer anastomosis device according to any of claims
1-25, wherein the blend comprising silk fibroin and plasticizer
further comprises an anti-restenosis agent.
27. The biopolymer anastomosis device according to any of claims
1-26, wherein the blend comprising silk fibroin and plasticizer
further comprises a cell.
28. A method comprising: implanting a first biopolymer anastomosis
device of any of claims 1-27 at a target site in a subject.
29. The method of claim 28, wherein the target site is a
tissue.
30. The method of claim 29, further comprising growing cells in the
anastomosis device.
31. The method of claim 28, wherein the target site is a blood
vessel.
32. The method of any of claims 28-31, wherein the silk
fibroin-based blend material of the anastomosis device swells upon
implantation at the target site, thereby reducing biopolymer
anastomosis device malapposition post-implantation.
33. The method of any of claims 28-32, wherein the biopolymer
anastomosis device comprises a therapeutic agent.
34. The method of claim 33, wherein the therapeutic agent is
stabilized, upon implantation, for at least 3 months or longer.
35. The method of any of claims 28-34, wherein the biopolymer
anastomosis device degrades as a tissue surrounding the target site
remodels or regenerates.
36. The method of any of claims 28-35, further comprising
implanting a second biopolymer anastomosis device of any of claims
1-27 at the same target site upon degradation of the first
anastomosis device.
37. The biopolymer anastomosis device according to any of claims
1-27, wherein the plasticizer is selected from the group consisting
of glycerol; ethylene glycol; propylene glycol; glyceryl
monostearate; 1,2-butylene glycol; 2,3-butylene glycol; styrene
glycol; polyethylene glycols such as diethylene glycol, triethylene
glycol, tetraethylene glycol; polyethylene glycols; polyethylene
oxides; monopropylene glycol monoisopropyl ether, propylene glycol
monoethyl ether, ethylene glycol monoethyl ether, diethylene glycol
monoethyl ether, sorbitol lactate; ethyl lactate; butyl lactate;
ethyl glycolate; allyl glycolate; monoethanolamine; diethanolamine;
triethanolamine; monisopropanolamine; triethylenetetramine;
2-amino-2-methyl-1,3-propanediol; and any combinations thereof.
37. A cell scaffold comprising a biopolymer anastomosis device of
any of claims 1-27, wherein the plasticizer is wherein the
plasticizer is glycerol and the blend comprising silk fibroin and
plasticizer further comprises a cell.
38. A method for joining a first blood vessel to a second blood
vessel, the method comprising inserting a first end of a hollow
tube into the first blood vessel and a second end of the hollow
tube into the second blood vessel and wherein the hollow tube is
formed of a blend that includes silk fibroin and a plasticizer.
39. The method according to claim 38 further comprising wrapping a
non-piercing suture around at least one of the first vessel and the
second vessel to secure at least one of the first vessel and the
second vessel to the hollow tube.
40. The method according to claim 38 further comprising positioning
an outer sleeve over the first end of the hollow tube after the
first end of the hollow tube has been inserted into the first
vessel to capture the first vessel between an outside diameter of
the first end and an inside diameter of the outer sleeve.
41. The method according to claim 40 further comprising positioning
a second outer sleeve over the second end of the hollow tube after
the second end of the hollow tube has been inserted into the second
vessel to capture the second vessel between an outside diameter of
the second end and an inside diameter of the second outer
sleeve.
42. The method according to claim 41 wherein at least of portion of
the second outer sleeve is positioned over the outer sleeve.
43. The method according to claim 40 wherein the first end includes
a first spherical enlarged portion and the outer sleeve includes an
internal thread that is adapted to mate with the spherical enlarged
portion after the first spherical enlarged portion is inserted into
the first blood vessel, wherein the outer sleeve can be rotating
into position over the first spherical enlarged portion to fasten
the first blood vessel to the first end.
44. The method according to claim 41 wherein the second end
includes a second spherical enlarged portion and the second outer
sleeve includes an internal thread that is adapted to mate with the
second spherical enlarged portion after the second spherical
enlarged portion is inserted into the second blood vessel, wherein
the second outer sleeve can be rotated into position over the
second spherical enlarged portion to fasten the second blood vessel
to the second end.
45. The biopolymer anastomosis device according to claim 1 wherein
at least one of the first end and the second end is beveled.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The present application claims the benefit of priority to
U.S. Provisional Patent Application Ser. No. 61/815,551, filed Apr.
24, 2013, the entire contents of which are incorporated herein by
reference.
BACKGROUND
[0003] 1. Technical Field
[0004] The invention relates to bioresorbable drug-eluting
biopolymer suture-free blood vessel anastomosis devices and methods
and systems for facilitating vascular anastomosis. Specifically,
the invention is directed to devices that can facilitate vascular
anastomosis by providing a quick mechanical union without the need
for suturing or tying knots. The bioresorbable biopolymer can
include silk fibroin, e.g., silk fibroin and blend that includes
silk fibroin, e.g., silk fibroin materials.
[0005] 2. Description of Certain Art
[0006] Manual suturing is the standard as a technique that
necessitates precise placement of sutures in the wall of blood
vessels to approximate their ends [4-7]. Current microsurgical
suturing techniques involve using fine (8-0 to 12-0) monofilament
nylon sutures mounted on sharp round needles. Vessels are prepared
under a microscope; vessels may be placed on a double approximating
clamp so that the ends can be approximated under no tension
[16,22].
[0007] Vessel couplers can enable the anastomosis of small diameter
vessels in cardiothoracic, vascular, and transplant surgery as well
as for microsurgical reconstructive procedures in plastic surgery.
Manual suturing requires extreme technical precision to prevent
long-term failure from foreign body reaction to the suture material
and intimal hyperplasia [4-7]. These factors and others have
contributed to persistent failure rates in 2-6% of cases [8,9].
Sutured anastomosis may be unreliable in small (<1.0 mm) or
diseased vessels with a tendency to fracture and develop clot, as a
contraindication to neovascularization. Furthermore, vascular
grafts continue to undergo thrombosis resulting in vascular
occlusion, prolonged hospital stays and death [10-15]. Even in
experienced hands, microvascular anastomosis remains a challenging
and time consuming procedure and has a steep learning curve for any
surgeon in training. Reconstitution of blood supply via vessel
anastomosis is technically challenging and requires expertise in
meticulous microsuturing technique. Technical suturing errors such
as uneven spacing, inversion of suture walls, and misalignment of
the vessel intima can lead to anastomotic leaks and thrombosis
which can be disastrous. For these reasons, alternatives to
traditional sutured microvascular anastomosis have been actively
investigated [16]. Different devices such as microclips, staples or
magnets have been used in an attempt to overcome the technical
difficulties of sutures (most of them have been designed for
large-caliber vessels greater than 2 mm in diameter) but have been
found to be traumatic to blood vessels resulting in failure rates
comparable to or higher than those of sutured anastomosis [17-21].
Sutureless vascular anastomosis is a technique gaining interest for
decreasing operative time and complexity [21].
SUMMARY
[0008] The present invention provides methods and systems that
utilize bioresorbable drug-eluting biopolymer materials to
construct suture-free blood vessel anastomosis devices. The devices
according to various embodiments of the invention can facilitate
vascular anastomosis by providing a quick mechanical union without
the need for suturing or tying knots and by providing grafting
material to span distances which would otherwise prevent direct
coaptation of the vessel segments. The biopolymer blend can be
non-injuring to the vessel lumen yet is able to maintain patency
while prevent kinking or twisting of the vessel. Disclosed
embodiments can be grouped into several different anastomosis
device families, which vary by anastomosis mechanism. These
embodiments complement each other and provide options for a broader
range of vessel joining applications. Each of the anastomosis
mechanisms according to the invention can provide different sets of
application specific benefits at varying levels of cost to
security, drug elution, or implantation speed. Although the
mechanical assemblies are structurally different, the design
components can be fabricated using the same bulk material, for
example, silk fibroin and blends including silk fibroin
materials.
[0009] Aastomosis devices according to various embodiments of the
invention can provide complete restorability, complex drug elution,
and highly tunable mechanical properties by using polymer
materials. These polymer based implants benefit from their
extensive use in tissue engineering. Unlike metallic counterparts,
polymer materials have been developed as scaffolds with control,
manipulation, and tailoring cellular processes and integration. In
addition, resorbable materials can be used to enable sutureless
anastomosis devices according to some embodiments of the invention
be resorbed by the body over time.
[0010] Degradation of resorbable magnesium alloys progresses as
pronounced surface pitting inhibits endothelialization [23] which
limits use as implant material [24]. Additionally, alloys are
limited to a thin polymer matrix for drug delivery [25]. Rather
than the simple corrosion degradation of magnesium implants, silk
fibroin:glycerol blends can facilitate controllable tissue
integration and implant resorption/degradation. Poly-L-lactic acid
which degrades by bulk erosion via hydrolysis of bonds between
repeating lactide units [26,27] has been shown to suffer from
shrinkage after vascular implantation in vivo [23].
Tyrosine-derived polycarbonate, which metabolizes to amino acids,
ethanol, and carbon dioxide [23] produced major adverse vascular
events in vivo, such as, myocardial infarction [23]. Poly(anhydride
ester) salicylic acid [28] releases salicylic acid as bonds are
hydrolyzed during surface erosion absorption [23], but has produced
intimal hyperplasia and restenosis in vivo [23]. Additionally,
polyglycolic acid/polylactic acid, polycaprolactone,
polyhydroxybutyrate/valerate, polyorthoester, and
polyethylencoxide/polybutylene terephthalate have induced
inflammatory reactions and fibrocellular proliferation within 2.5-
to 3.0-mm diameter coronary arteries [29].
[0011] In contrast to these polymers, silk fibroin has been
reported to be less immunogenic and inflammatory and has been
reported to be used successfully in small diameter blood vessels in
a number of animal studies [30-32]. Unlike the tyrosine-derived
polycarbonate, salicylate, and magnesium alloys, our silk fibroin
material swells slightly after hydrated, in physiological
conditions [33]. This property of silk fibroin improves vessel
fitment and makes them more secure, in contrast to the shrinking
observed with polylactic acid implants [23]. Our design and
material have been developed after surveying the advancements and
limitations of competitive approaches. Our device is uniquely
suited to minimize implant induced injury and promote vascular
healing. The polymer implant has high radial strength yet is
compliant at the tissue interface. The silk fibroin-based system
prevents vessel stenosis at the site of anastomosis and delivers
sophisticated drug treatments enabling complete resorption and
healthy vessel remodeling. The micro-permeable material allows
nutrient exchange but will not allow erosion of the vessel wall
eliminating hyperplasia driven restenosis. Silk fibroin Biomaterial
Systems The flexibility of silk fibroin processing allows for the
formation of silk fibroin films and other more complex composite
materials [34].
[0012] Slow Degradation--Silk fibroin biomaterials degrade to amino
acids slowly over the course of weeks to years [31], without
chemical or photoinitiated crosslinking, unlike collagens and many
other polymeric biomaterials.
[0013] Biocompatibility--Silk fibroins have been used as sutures
for decades (FDA approved) are biocompatible and are less
immunogenic and inflammatory than other common degradable polymers
(collagens or polyesters such as PLGA) [32,35]. There are no known
bioburdens in silk fibroins, unlike persistent concerns with
collagens [36]. Silk fibroin medical devices have recently expanded
into new applications based on FDA approval (Serica, Inc., recently
purchased by Allergan, Inc.).
[0014] Mechanical Properties and Sterilization--Silk fibroins offer
robust mechanical properties in many formats [36,37]. These
materials can also be autoclaved for sterilization without loss of
mechanical integrity [36].
[0015] Functionalization--Proteins can be adsorbed to silk fibroin,
or chemically linked. For example, silk fibroin matrices can be
functionalized with cell growth factors and peptides with direct
control over placement and density of these factors using nontoxic
and biocompatible chemistries [38-40].
[0016] Stabilization and Controlled Release of Therapeutics In Silk
fibroin--The bioresorbable silk fibroin can deliver greater drug
payloads and more complex drug release over longer time periods
thereby limiting the occurrence of localized restenosis throughout
the process of implant resorption [41,42]. Polarized drug elution
can provide more control of endothelial stimulation and inhibition
of smooth muscle. Enzymes, antibiotics, vaccines and antibodies can
be entrapped in silk fibroin protein biomaterials, resulting in
remarkable stabilization even at relatively high temperatures and
without specialized storage conditions [43-45]. For example,
stabilization of antibiotics and enzymes for months or up to one
year at 37.degree. C. underscores the versatility and potential of
this technology. We have also demonstrated that various
therapeutics to regulate vascular cell responses can be
incorporated into silk fibroin materials and in turn, regulate
endothelial and vascular cell outcomes [331,46,47]. In addition
silk fibroin materials can control the release profile of many
biological samples including proteins [43,45,48,49].
[0017] Chronic Interfacial Injury--We can fine tune the stiffness
of the material to match natural vessels. Each film will exhibit
time dependent reductions in stiffness throughout the degradation
in vivo. In particular, this enables us to pinpoint the optimal
implant mechanical stiffness which is time-dependent with respect
to endothelialization and prevention of adventitial angiogenic
hyperplasia. The optimal mechanical properties will reduce
proliferative thickening and inflammation, subsequently reducing
vessel healing time. This will in turn reduce the required implant
mechanical radial strength, which would have been needed to combat
the implant induced restenosis at later time points, and ultimately
allow for implant resorption and degradation of mechanical
function.
[0018] These and other capabilities of the invention, along with
the invention itself, will be more fully understood after a review
of the following figures, detailed description, and claims.
BRIEF DESCRIPTION OF THE DRAWING
[0019] The Drawing included herein is comprised of the following
several Figures:
[0020] FIG. 1 shows a polymer anastomosis device according to a
first embodiment of the invention.
[0021] FIG. 2 shows a polymer anastomosis device according to a
second embodiment of the invention.
[0022] FIG. 3 shows a polymer anastomosis device according to a
third embodiment of the invention.
[0023] FIG. 4 shows a cross-sectioned view of the polymer
anastomosis device shown in FIG. 3.
[0024] FIG. 5 shows a polymer anastomosis device according to a
fourth embodiment of the invention.
[0025] FIG. 6 shows a polymer anastomosis device according to a
fifth embodiment of the invention.
[0026] FIG. 7 shows a diagrammatic exploded view of a polymer
anastomosis device according to the fifth embodiment of the
invention.
[0027] FIG. 8a shows a process flow for silk fibroin/NaCl blending
and leaching method that can be used to incorporate nano-porosity
into the anastomosis device walls according to some embodiments of
the invention.
[0028] FIG. 8b shows a scanning electron micrographs (SEM)
demonstrate morphology of the final tubes fabricated according to
some embodiments of the invention.
[0029] FIG. 9a shows a process flow for silk fibroin/PMMA blending
and leaching method used to incorporate nano-porosity into the
anastomosis device walls according to some embodiments of the
invention.
[0030] FIG. 9b shows a SEM of the final material fabricated
according to the method shown in FIG. 9a according to some
embodiments of the invention.
[0031] FIG. 10 shows a chart of the radial compressive resistance
of the tubular component used in anastomosis device fabricated
according to some embodiments of the invention.
[0032] FIGS. 11a, 11b and 11c show optimized diameter sizing of
polymer anastomosis devices according to some of the embodiments of
the invention.
[0033] FIG. 12. Process flow of device fabrication: a) Coating of
rods for clip and coupler components; b) Spherical barb tip
deposition for coupler components; c) Removal of tubes from rods
for clip components; d) Removal of tubes with spherical barbs from
rods for couplers; c) Initial trimming of coupler components; f)
Initial trimming of clip components from tube, and creation of
seats using biopsy punch.
[0034] FIGS. 13. (A-F) (a) Schematic of assembled components (b)
cross-section view; (c-f) method ofanastomosis, (c, d) first the
clip was inserted over the vessel followed by (d, e) inserting the
coupler into the vessel. (e, f) Finally, the clip is then slid
toward the coupler and locked into place by aligning the seats over
around the barbs.
[0035] FIG. 14 Phase contrast images of (a) the coupler device barb
and edge of the luminal opening; (b) high and low magnification of
the hydrated coupler device cross-section showing
[0036] FIG. 15 Mounting method for (a-b) mechanical testing of
compression to insertion; (c) tensile testing procedure; (d) radial
compressive resistance of the tubular component used in anastomosis
device fabrication. Crush resistance of 5 different implant wall
thickness are compared to femoral vein (F.V.) and artery (F.A.) and
a clinically available metal self-expanding stent (MSES) (Boston
Scientific Wallstent); (e) Effect of 50% vessel wall compression on
insertion force and pull-out retention strength.
[0037] FIGS. 16 (A-C) (a) Bench top flow loop and burst chamber
designed for this work; (b) maximum supported flow rate and burst
pressure per compression fitting tightness; (c) Interferograms
measuring implant luminal surface roughness after 1, 30, and 180
days of aqueous storage.
[0038] FIGS. 17 (A-D) Schematic comparing the sizes of components
used to produce the four fitments which varied in tightness. *ID is
the inner diameter of the clip. **BD is the outer diameter of the
ellipsoid barb tips.
[0039] FIGS. 18 (A-E) (a) Schematic describing the procedure of
loading devices with Heprain (top) bulk loading via hydration in
hepariniized solution (bottom) inner wall coating; (b) perfusion
system used to perform the release studies; (c) standard curve; (d)
total quantity of Heprain released from the devices over 24 hours
time period; (c) amount of remant drug retained in the devices at
0, 1, or 24 hours.
[0040] FIG. 19 Digital photograph of the completed anastomosis of a
transected porcine femoral vein segments using the sutureless silk
device.
[0041] FIGS. 20 (A-D) (a) H & E staining of the occlusion
developed within the device (b) Factor VIII demonstrate the
recanalization is lined with endothelial cells (c) Trichrome
staining reveal collagen has been deposited within the occlusion
(d) Cells within the occlusion and recanalization are positive for
smooth muscle actin suggesting smooth muscle hyperplasia.
[0042] FIGS. 21 (A-D) Schematic of components and method of
anastomosis.
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
[0043] The present invention is directed to biorsorbable biopolymer
suture-free blood vessel anastomosis devices and methods for their
use. In some embodiments, such anastomosis devices are also capable
of releasing therapeutics, anti-coagulants, or other active agents.
In accordance with various embodiments of the invention,
anastomosis devices can provide vascular anastomosis using a
mechanical union without the need for suturing or tying knots. In
accordance with various embodiments of the invention, anastomosis
devices can span distances which would otherwise prevent direct
coaptation of the vessel segments.
Exemplary Devices
[0044] FIG. 1 shows an anastomosis device 100 according to some
embodiments of the invention. In this embodiment, the anastomosis
device 100 includes a hollow tube 110 formed of a polymeric
material that extends along a longitudinal axis from a first end
112 to a second end 114 and each end can be pressed into the lumen
of opposing vessel segments a shown in FIGS. 1b, 1c and 1d. The one
or both ends 112, 114 can be cut 90.degree. to the longitudinal
axis or can include a non-piercing 45.degree. beveled tip to
facilitate implantation. A non-piercing suture 120 can be wrapped
around the vessel to secure the anastomosis device at one or both
ends. The suture can be fabricated by coating fine-drawn dextrose
rods with HFIP solubilized silk fibroin. This embodiment of the
invention can used to join vessel segments that have very small
diameters. For example, this embodiment can be used in lymphatics
or micro-channeling where 100 to 500 .mu.m lumen vessels are to be
joined. In accordance with some embodiments of the invention, the
wall thickness of the hollow tube can be in the range from 50 to
150 .mu.m. Upon removal of clamps and restoration of blood flow,
blood passes from the proximal vessel segment through the lumen of
the implanted hollow tube then into the distal vessel segment.
Blood flow contacts the luminal surface of the anastomosis device
which can be coated or bulk loaded with a variety of established
vascular antithrombotic, anti-proliferative, or antibiotic drugs.
This embodiment of the invention can be implanted very quickly and
can facilitate anastomosis in small diameter vessels, for example,
in the range from 100 to 500 .mu.m. This embodiment can also be
used where the vessel segment length is very limited and in
application where it is desirable to span short vessel segment gaps
to serve dual functions, as a grafting material as well as
performing anastomosis. In some embodiments, the device 100 of FIG.
1 is prepared from a bulk material that is 100% silk and is derived
by solubilizing the protein in HFIP, for example as described
herein.
[0045] FIG. 2 shows an anastomosis device 200 according to some
embodiments of the invention. In this embodiment, the anastomosis
device 200 includes a hollow tube 210 formed of a polymeric
material that extends along a longitudinal axis from a first cod
212 to a second end 214 and each end can be pressed into the lumen
of opposing vessel segments as shown in FIGS. 2b, 2c and 2d. One or
both ends 212, 214 can include spherical barbs or bulges which can
be pressed into the lumen of opposing vessel segments. In
accordance with some embodiments of the invention, the diameter of
the spherical barbs can be in the range of 110% to 140% of the
vessel inner diameter, for example, approximately 125% of the
vessel inner diameter in order to provide increased frictional
retaining forces on the outside surface of the anastomosis device.
Each end of the device can include a rounded tip 212, 214 which can
aid in sealing and securing the anastomosis device without inducing
chronic injury at the implant/tissue interface. After the spherical
tips have been inserted, a non-piercing suture 220 can be wrapped
around each vessel to secure the vessel to the anastomosis device
200. For example, this embodiment can be used where 500 to 5000
.mu.m lumen vessels are to be joined. In accordance with some
embodiments of the invention, the wall thickness of the hollow tube
210 can be in the range from 100 to 250 .mu.m. Upon removal of
clamps and restoration of blood flow, blood passes from the
proximal vessel segment through the lumen of the implanted hollow
tube then into the distal vessel segment. Blood flow contacts the
luminal surface of the anastomosis device which can be coated or
bulk loaded which a variety of established vascular antithrombotic,
anti-proliferative, or antibiotic drugs. This embodiment of the
invention can be implanted very quickly and can facilitate
anastomosis where vessel segment length is very limited. Where
necessary, the anastomosis devices according to this embodiment can
span short vessel segment gaps to serve dual functions as a
grafting material as well as performing anastomosis. This
embodiment of the invention can provide improved connection
security over that of the device shown in FIG. 1. In some
particular embodiments, the device 200 of FIG. 2 is prepared from a
bulk material that comprises or consists of a silk:glycerol blend
in a dry weight ratio of 75:25, for example fabricated as described
herein.
[0046] FIG. 3 shows an anastomosis device 300 according to some
embodiments of the invention. In this embodiment, the anastomosis
device 300 includes a first tube 310 formed of a polymeric material
that extends along a longitudinal axis and has one or more
circumferential rows of microneedles 312 protruding radially
outward at one or more locations along tube 310 and a second tube
314 formed of a polymeric material. The length and diameter of the
microneedles 312 can be determined by the characteristics of the
vessel walls, including, for example, the vessel wall thickness. In
accordance with some embodiments of the invention, the preferred
microneedle 312 length can be approximately 180% of the vessel wall
thickness. In accordance with some embodiments of the invention,
the wall thickness of the first tube 310 can be in the range from
100 .mu.m to 400 .mu.m and in some embodiments, approximately 250
rpm. In some particular embodiments, the device 300 of FIG. 3 is
prepared from a bulk material that comprises or consists of a
silk:glycerol blend in a dry weight ration of 75:25, for example
fabricated as described herein.
[0047] FIG. 4 shows a cross-section of the anastomosis device shown
in FIG. 3. In accordance with some embodiments, the second tube 314
can be configured with an inner diameter that enables it to be
positioned over the first tube 310 and the array of microneedles
312 as well as one or more layers of vessel wall. In accordance
with some embodiments of the invention, the second tube 314 can
have an inner diameter equivalent to the outer diameter of the
first tube 310 (e.g., L+P+P+1+1), plus the height, M, of the
microneedles 314. In accordance with some embodiments of the
invention, the wall thickness of the second tube 310 can be in the
range from 100 .mu.m to 200 .mu.m and in some embodiments,
approximately 150 .mu.m.
[0048] FIGS. 3a-3g show an anastomosis procedure according to some
embodiments of the invention. In accordance with the invention, the
first tube 310 can be slid around the proximal vessel segment,
vessel 1, and the second tube 314 can be slid around the distal
vessel segment, vessel 2 as shown in FIG. 3a. Next, the proximal
vessel, vessel 1 can be inverted around the first tube 310, and the
distal vessel, vessel 2 can be inverted around second tube 314 as
shown in FIG. 3b. The inverted vessel segment ends can be brought
together concentrically as shown in FIG. 3c. While supporting the
first tube 310 and the inverted proximal segment of the proximal
vessel, vessel 1 steady, the second tube 314 can be slide over the
first tube 310 and the microneedles 312, which will unroll the
inverted portion of the distal vessel segment over the first tube
310 and the microneedles 312 as shown in FIGS. 3d and 3e. The
microneedles 312 can pierce and fix the vessels in place and the
assembly can be maintained by compression fitting the second tube
314 over the first tube 310, completing anastomosis as shown in
FIGS. 3f and 3g. The proximal segment remains inverted around Part
1, exposing the inner surface of the proximal segment of vessel 1
in direct contact with inner surface of the distal vessel segment,
vessel 1 and also concentrically wraps the first tube 310. As shown
in FIG. 4, the microneedles 312 of the first tube 310 can penetrate
through both vessel walls.
[0049] Upon removal of clamps and restoration of blood flow, blood
passes from the proximal vessel segment directly to the lumen of
the distal vessel segment. Blood flow contacts only the endothelial
surfaces of blood vessels and does not contact the anastomosis
device, which nearly eliminates thrombotic risk. In accordance with
this embodiment of the invention, the device 300 including the
microneedles 312 can be coated or bulk loaded with a variety of
established vascular antithrombotic, anti-proliferative, or
antibiotic drugs. The anastomosis devices according to this
embodiment of the invention can be used where vessels having a
lumen diameter of approximately 2500 .mu.m or greater are to be
joined. In addition, this embodiment of the invention can be used
in pairs in conjunction with vascular grafting materials and
procedures. Where necessary, devices according to this embodiment
can span short vessel segment gaps to serve dual function as a
grafting material as well as performing anastomosis. The
anastomosis produced according to this embodiment of the invention
can be very secure. The implantation speed of the anastomosis
device according to this embodiment of the invention can be in the
range from 1 to 7 minutes.
[0050] FIG. 5 shows an anastomosis device 500 according to some
embodiments of the invention. In this embodiment, the anastomosis
device 500 includes a first tube 510 formed of a polymeric material
that extends along a longitudinal axis from a first end 512 to a
second end 514 and has one or more circumferential rows of
microneedles 512A, protruding radially outward at the first end 512
and microneedles 514A, protruding radially outward at the second
end 514, a second tube 514 formed of a polymeric material and a
third tube 516 formed of a polymeric material. In some particular
embodiments, the device 500 of FIG. 5 is prepared from a bulk
material that comprises or consists of a silk:glycerol blend in a
dry weight ration of 75:25, for example fabricated as described
herein.
[0051] FIG. 5 also shows an anastomosis procedure according to some
embodiments of the invention. In accordance with the invention, the
second tube 516 can be slid around the proximal vessel segment,
vessel 1, and the third tube 518 can be slid around the distal
vessel segment as shown in FIG. 5a. Next, the proximal vessel,
vessel 1 can be inverted around second tube 516, and the distal
vessel, vessel 2 can be inverted around third tube 518 as shown in
FIG. 5b. The inverted vessel segment ends can be brought together
concentrically at each end 512 and 514 of the first tube 310 as
shown in FIG. 5c. While holding the first tube 510 steady, the
second tube 516 can slid over the first end 512, which will unroll
the inverted proximal vessel segment over the microneedles 512A at
the first end 512 of the first tube 510 as shown in FIGS. 5d-5e.
Similarly, the third tube 518 can slid over the second end 514,
which will unroll the inverted distal vessel segment over the
microneedles 514A at the second end 514 of the first tube 510 as
shown in FIGS. 5d-5c. The microneedles 512A and 514A can pierce and
fix the vessels in place and the assembly can be maintained by
compression fitting the second tube 516 over the first end 512 and
the third tube 518 over the second end 514, completing anastomosis
as shown in FIGS. 5e-5f.
[0052] Upon removal of clamps and restoration of blood flow, blood
passes from the proximal vessel segment through the lumen of the
first tube 510 then into the distal vessel segment. Blood flow
contacts the luminal surface of the anastomosis device 500 which
can be coated or bulk loaded with a variety of established vascular
antithrombotic, anti-proliferative, or antibiotic drugs. Where
necessary, devices according to this embodiment can span short
vessel segment gaps to serve dual function as grafting material as
well as performing anastomosis. The anastomosis devices according
to this embodiment of the invention can be used where vessels
having a lumen diameter of approximately 2500 .mu.m or greater are
to be joined. The anastomosis produced according to this embodiment
of the invention can be very secure. The implantation speed of the
anastomosis device according to this embodiment of the invention
can be in the range from 2 to 9 minutes.
[0053] FIGS. 6 and 7 show an anastomosis device 600 according to
some embodiments of the invention. In this embodiment, the
anastomosis device 600 includes a first tube 610 formed of a
polymeric material that extends along a longitudinal axis from a
first end 612 to a second end 614 and each end 612, 614 can be
pressed into the lumen of opposing vessel segments as shown in
FIGS. 6c, 6d, 6e and 6f. One or both ends 612, 614 can include
spherical barbs or bulges which can be pressed into the lumen of
opposing vessel segments. In accordance with some embodiments of
the invention, the diameter of the spherical barbs can be in the
range of 110% to 140% of the vessel lumen diameter, for example,
approximately 125% of the vessel lumen diameter in order to provide
increased frictional retaining forces on the outside surface of the
anastomosis device. Each end of the device can include a rounded
tip 612, 614 which can aid in scaling and securing the anastomosis
device without inducing chronic injury at the implant/tissue
interface. The anastomosis device 600 can also include a first
tubular sheath 616 formed of a polymeric material and a second
tubular sheath 618 formed of a polymeric material. The first
tubular sheath 616 and the second tubular sheath 618 can each
include a single or double helical thread channel that can be sized
to mate with the spherical tip on each end 612 and 614 of the first
tube 610. The inner thread flank of each tubular sheath 616 and
618, progresses to the thread root at a curvature matching the
exterior of each spherical tip on the ends 612 and 614 of the first
tube 610. This enables each tubular sheath 616 and 618 to be
threaded over each respective spherical tip on the ends 612 and 614
of the first tube 610 after each tip is inserted into the lumen of
the respective vessels as shown in FIGS. 6c-6d. In accordance with
some embodiments of the invention, the wall thickness of the first
tube 610 can be in the range from 100 .mu.m to 300 .mu.m and in
some embodiments, approximately 150 .mu.m to 250 .mu.m. In
accordance with some embodiments of the invention, the wall
thickness of the first tubular sheath 616 and the second tubular
sheath 618 can be in the range from 100 .mu.m to 300 .mu.m and in
some embodiments, approximately 150 .mu.m. In some particular
embodiments, the device 600 of FIGS. 6 and 7 is prepared from a
bulk material that comprises or consists of a silk:glycerol blend
in a dry weight ratio of 75:25, for example fabricated as described
herein.
[0054] FIG. 6 also shows an anastomosis procedure according to some
embodiments of the invention. In accordance with the invention, the
second tubular sheath 616 can be slid around the proximal vessel
segment, vessel 1, and the third tubular sheath 618 can be slid
around the distal vessel segment as shown in FIG. 6a. Next, the
spherical tip on first end 612 can be inserted into the lumen of
the proximal vessel, vessel 1, and the spherical tip on second end
614 can be inserted into the lumen of the distal vessel as shown in
FIGS. 6b and 6c. Next, the second tubular sheath 618 can be is slid
toward the second end 614 of the first tube 610 and rotated around
the anastomosis to securely lock the distal vessel, vessel 2 to the
spherical tip on the second end 614 of the first tube 610 as shown
in FIG. 6d. Next, the first tubular sheath 616 can be is slid
toward the first end 612 of the first tube 610 and rotated around
the anastomosis to securely lock the proximal vessel, vessel 1 to
the spherical tip on the first end 612 of the first tube 610 as
shown in FIGS. 6e and 6f. The first tubular sheath 616 can include
a cuff or extension to facilitate circumferential alignment with
second tubular sheath 618 so that the first tubular sheath 616 can
be fastened around the second tubular sheath 618, thereby locking
the position of the vessels and implant.
[0055] Upon removal of clamps and restoration of blood flow, blood
passes from the proximal vessel segment through the lumen of the
first tube 610 then into the distal vessel segment. Blood flow
contacts the luminal surface of the anastomosis device 600 which
can be coated or bulk loaded with a variety of established vascular
antithrombotic, anti-proliferative, or antibiotic drugs. Where
necessary, devices according to this embodiment can span short
vessel segment gaps to serve dual function as grafting material as
well as performing anastomosis. The anastomosis devices according
to this embodiment of the invention can be used where vessels
having a lumen diameter of approximately 500 .mu.m to 5000 .mu.m or
greater are to be joined. The anastomosis produced according to
this embodiment of the invention can be very secure and the helical
sheath can provide protection for tissue in-growth. The
implantation speed of the anastomosis device according to this
embodiment of the invention can be in the range from 1 to 6
minutes.
[0056] Each of the embodiments of the invention can be fabricated
using silk fibroin materials and blends that include silk fibroin.
The use these silk fibroin materials can provide the ability to
load and deliver therapeutic compounds and 100% degradability of
the silk fibroin material over time. While each of the embodiments
can be fabricated using bulk materials consisting of 100% silk
fibroin (for example, the embodiment of FIG. 1), fabricating the
embodiments using bulk materials that include a blend of silk
fibroin and a plasticizer, such as glycerol can also be used. In
some particular embodiments, for example, a device is prepared from
a bulk material that comprises or consists of a silk:glycerol blend
in a dry weight ration of 75:25, for example fabricated as
described herein.
Evaluation of Devices
[0057] In accordance with some embodiments of the invention, the
anastomosis seal was evaluated using a peristaltic pump. In this
example, porcine carotid arteries were excised and mounted inline
of a pump-driven aqueous flow loop using barb fittings, and secured
circumferentially with silk fibroin sutures. The arteries were
transected and anastomosed using each of the embodiments described
here for comparison. Flow was increased by 100 mLmin.sup.-1 each
hour until reaching 1600 mLmin.sup.-1, which is 7 times greater
than physiological flow and velocity.
[0058] In accordance with some embodiments of the invention, the
target vessel diameters can be clinically evaluated prior to
implantation. With this information, anastomosis devices can be
sized appropriately. Flow studies have found seals perform
optimally when the device internal diameter (I.D.) is equal to the
loaded I.D. of the blood vessel, and the blood vessel wall is
displaced an additional 11.5% by the implant wall. For example, as
shown in FIG. 11a, if the vessel I.D. is 2.6 mm, then an
appropriately sized anastomosis device would have an I.D. of 2.6 mm
but an outer diameter (O.D.) of 2.9 mm and a wall thickness of 150
.mu.m. However, mechanical evaluation has shown the walls of these
anastomosis devices to produce superior strength when the thickness
is in the range of 250 .mu.m to 300 .mu.m. For this reason, it is
desirable to incorporate thicker implant walls. After reevaluation,
optimal fitting in the blood vessel from the previous example
exhibiting a loaded I.D. of 2.6 mm, can be accomplished using a
anastomosis device having an I.D. of 2.5 mm but an outer diameter
(O.D.) of 3 mm (and a wall thickness of 250 .mu.m), producing an
additional 15.5% dilation rather than 11.5%. Preliminary surgical
implantations have revealed that the embodiments of FIGS. 2 and 6,
which use spherical tips as part of the anastomosis mechanism,
require reconsideration of the implant dimensions to facilitate the
procedure and provide acceptable scaling. Where the spherical tip
over-dilates the target vessel in the range of 15%, the internal
diameter of the implant can be equivalent to 80% of the sphere
outer diameter. This facilitates implantation, sealing, and
securing of the anastomosis. Preliminary in vitro flow testing of
anastomosis devices according to the embodiments shown in FIGS. 3
and 5, has suggested compression of the load-dilated vessel wall to
90% can be used to produce a secure seal.
Materials
[0059] Silk Fibroin
[0060] In accordance with some embodiments of the invention, the
bulk material, i.e., polymeric material, of the anastomosis device
comprises silk fibroin. As used herein, the term "silk fibroin" or
"fibroin" includes silkworm fibroin and insect or spider silk
protein. See e.g., Lucas et al., 13 Adv. Protein Chem. 107 (1958).
Any type of silk fibroin can be used according to aspects of the
present invention. Silk fibroin produced by silkworms, such as
Bombyx mori, is the most common and represents an earth-friendly,
renewable resource. For instance, silk fibroin used in can be
attained by extracting sericin from the cocoons of B. mori. Organic
silkworm cocoons are also commercially available. There are many
different silks, however, including spider silk (e.g., obtained
from Nephila clavipes) transgenic silks, genetically engineered
silks (recombinant silk), such as silks from bacteria, yeast,
mammalian cells, transgenic animals, or transgenic plants, and
variants thereof, that can be used. See for example, WO 97/08315
and U.S. Pat. No. 5,245,012, content of both of which is
incorporated herein by reference in its entirety. In some
embodiments, silk fibroin can be derived from other sources such as
spiders, other silkworms, bees, and bioengineered variants thereof.
In some embodiments, silk fibroin can be extracted from a gland of
silkworm or transgenic silkworms. See for example, WO2007/098951,
content of which is incorporated herein by reference in its
entirety. In some embodiments, silk fibroin is free, or essentially
free, of sericin.
[0061] The silk fibroin solution can be prepared by any
conventional method known to one skilled in the art. For example,
B. mori cocoons are boiled for about 30 minutes in an aqueous
solution. In one embodiment, the aqueous solution is about 0.02M
Na.sub.2CO.sub.3. The cocoons are rinsed, for example, with water
to extract the sericin proteins and the extracted silk fibroin is
dissolved in an aqueous salt solution. Salts useful for this
purpose include lithium bromide, lithium thiocyanate, calcium
nitrate or other chemicals capable of solubilizing silk fibroin. In
some embodiments, the extracted silk fibroin is dissolved in about
8M-12 M LiBr solution. The salt is consequently removed using, for
example, dialysis.
[0062] If necessary, the solution can then be concentrated using,
for example, dialysis against a hygroscopic polymer, for example,
PEG, a polyethylene oxide, amylose or sericin. In some embodiments,
the PEG is of a molecular weight of 8,000-10,000 g/mol and has a
concentration of about 10% to about 50% (w/v). A slide-a-lyzer
dialysis cassette (Pierce, MW CO 3500) can be used. However, any
dialysis system can be used. The dialysis can be performed for a
time period sufficient to result in a final concentration of
aqueous silk fibroin solution between about 10% to about 30%. In
most cases dialysis for 2-12 hours can be sufficient. See, for
example, International Patent Application Publication No. WO
2005/012606, the content of which is incorporated herein by
reference in its entirety.
[0063] Alternatively, the silk fibroin solution can be produced
using organic solvents. Such methods have been described, for
example, in Li, M., et al., J. Appl. Poly Sci. 2001, 79, 2192-2199;
Min, S., et al. Sen'I Gakkaishi 1997, 54, 85-92; Nazarov, R. et
al., Biomacromolecules 2004 May-June; 5(3):718-26, content of all
which is incorporated herein by reference in their entirety. An
exemplary organic solvent that can be used to produce a silk
fibroin solution includes, but is not limited to,
hexafluoroisopropanol (HFIP). See, for example, International
Application No. WO2004/000915, content of which is incorporated
herein by reference in its entirety. Accordingly, in some
embodiments, the solution comprising the silk fibroin comprises an
organic solvent, e.g., HFIP. In some other embodiments, the
solution comprising the silk fibroin is free or essentially free of
organic solvents.
[0064] Generally, any amount of silk fibroin can be present in the
solution. For example, amount of silk fibroin in the solution can
be from about 1% (w/v) to about 50% (w/v) of silk fibroin, e.g.,
silk fibroin. In some embodiments, the amount of silk fibroin in
the solution can be from about 1% (w/v) to about 35% (w/v), from
about 1% (w/v) to about 30% (w/v), from about 1% (w/v) to about 25%
(w/v), from about 1% (w/v) to about 20% (w/v), from about 1% (w/v)
to about 15% (w/v), from about 1% (w/v) to about 10% (w/v), from
about 5% (w/v) to about 25% (w/v), from about 5% (w/v) to about 20%
(w/v), from about 5% (w/v) to about 15% (w/v). Exact amount of silk
fibroin in the silk fibroin solution can be determined by drying a
known amount of the silk fibroin solution and measuring the mass of
the residue to calculate the solution concentration.
[0065] Additives
[0066] In some embodiments, the bulk material of the anastomosis
device comprises one or more (e.g., one, two, three, four, five or
more) additives. Without wishing to be bound by a theory, additives
can provide one or more desirable properties to the anastomosis
device, e.g., strength, flexibility, ease of processing and
handling, biocompatibility, bioresorability, lack of air bubbles,
surface morphology, and the like. The additive can be covalently or
non-covalently linked with silk fibroin and can be integrated
homogenously or heterogeneously within the bulk material. The
additive can be in any physical form. For example, the additive can
be in the form of a particle (e.g., microparticle or nanoparticle),
a fiber, a film, a gel, a mesh, a mat, a non-woven mat, a powder, a
liquid, or any combinations thereof. The bulk material of the
anastomosis device containing the additive can be formulated by
mixing one or more additives with the silk fibroin-fibroin solution
used to make the stent.
[0067] Without limitations, the additive can be selected from the
group consisting of anti-proliferative agents, biopolymers,
nanoparticles (e.g., gold nanoparticles), proteins, peptides,
nucleic acids (e.g., DNA, RNA, siRNA, modRNA), nucleic acid
analogs, nucleotides, oligonucleotides, peptide nucleic acids
(PNA), aptamers, antibodies or fragments or portions thereof (e.g.,
paratopes or complementarity-determining regions), antigens or
epitopes, hormones, hormone antagonists, growth factors or
recombinant growth factors and fragments and variants thereof, cell
attachment mediators (such as RGD), cytokines, enzymes, small
molecules, antibiotics or antimicrobial compounds, toxins,
therapeutic agents and prodrugs, small molecules and any
combinations thereof.
[0068] Ratio of the silk fibroin to the total amount of additives
in the bulk material can range from 100:1 to 1:100. For example,
the ratio of silk fibroin to additive can range from 50:1 to 1:50,
from 25:1 to 1:25, from 20:1 to 1:20, from 15:1 to 1:15, from 10:1
to 1:10, or from 5:1 to 1:5. In some embodiments, the ratio of silk
fibroin to additive can be from 5:1 to 1:1. In one embodiment, the
ratio of silk fibroin to additive can be 3:1. The ratio can be
molar ratio, weight ratio, or volume ratio.
[0069] In some embodiments, the additive is a plasticizer. As used
herein, the term "plasticizer" is intended to designate a compound
or a mixture of compounds that can increase flexibility,
processability and extensibility of the polymer in which it is
incorporated. A plasticizer can reduce the viscosity of the melt,
lower the second order transition temperatures and the elastic
modulus of the product. Suitable plasticizers include, but are not
limited to, low molecular weight polyols having aliphatic hydroxyls
such as ethylene glycol; propylene glycol; propanetriol (i.e.,
glycerol); glyceryl monostearate; 1,2-butylene glycol; 2,3-butylene
glycol; styrene glycol; polyethylene glycols such as diethylene
glycol, triethylene glycol, tetraethylene glycol and other
polyethylene glycols having a molecular weight of about 1,000 or
less; polypropylene glycols of molecular weight 200 or less; glycol
ethers such as monopropylene glycol monoisopropyl ether; propylene
glycol monoethyl ether; ethylene glycol monoethyl ether, diethylene
glycol monoethyl ether; ester-type plasticizers such as sorbitol
lactate, ethyl lactate, butyl lactate, ethyl glycolate, allyl
glycolate; and amines such as monoethanolamine, diethanolamine,
triethanolamine, monoisopropanolamine, triethylenetetramine,
2-amino-2-methyl-1,3-propanediol, polymers and the like. In one
embodiment, the plasticizer can include glycerol.
[0070] In some embodiments, the additive is a polymer. In some
embodiments, the polymer is a biocompatible polymer. As used
herein, the term "biocompatible polymer" refers to any polymeric
material that does not deteriorate appreciably and does not induce
a significant immune response or deleterious tissue reaction, e.g.,
toxic reaction or significant irritation, over time when implanted
into or placed adjacent to the biological tissue of a subject, or
induce blood clotting or coagulation when it comes in contact with
blood. Exemplary biocompatible polymers include, but are not
limited to, a poly-lactic acid (PLA), poly-glycolic acid (PGA),
poly-lactide-co-glycolide (PLGA), polyesters, poly(ortho ester),
poly(phosphazine), poly(phosphate ester), polycaprolactone,
gelatin, collagen, fibronectin, keratin, polyaspartic acid,
alginate, chitosan, chitin, hyaluronic acid, pectin,
polyhydroxyalkanoates, dextrans, and polyanhydrides, polyethylene
oxide (PEO), poly(ethylene glycol) (PEG), triblock copolymers,
polylysine, alginate, polyaspartic acid, any derivatives thereof
and any combinations thereof. Other exemplary biocompatible
polymers amenable to use according to the present disclosure
include those described for example in U.S. Pat. No. 6,302,848;
U.S. Pat. No. 6,395,734; U.S. Pat. No. 6,127,143; U.S. Pat. No.
5,263,992; U.S. Pat. No. 6,379,690; U.S. Pat. No. 5,015,476; U.S.
Pat. No. 4,806,355; U.S. Pat. No. 6,372,244; U.S. Pat. No.
6,310,188; U.S. Pat. No. 5,093,489; U.S. Pat. No. 387,413; U.S.
Pat. No. 6,325,810; U.S. Pat. No. 6,337,198; U.S. Pat. No.
6,267,776; U.S. Pat. No. 5,576,881; U.S. Pat. No. 6,245,537; U.S.
Pat. No. 5,902,800; and U.S. Pat. No. 5,270,419, content of all of
which is incorporated herein by reference.
[0071] In some embodiments, the biocompatible polymer is PEG or
PEO. As used herein, the term "polyethylene glycol" or "PEG" means
an ethylene glycol polymer that contains about 20 to about 2000000
linked monomers, typically about 50-1000 linked monomers, usually
about 100-300. PEG is also known as polyethylene oxide (PEO) or
polyoxyethylene (POE), depending on its molecular weight. Generally
PEG, PEO, and POE are chemically synonymous, but historically PEG
has tended to refer to oligomers and polymers with a molecular mass
below 20,000 g/mol, PEO to polymers with a molecular mass above
20,000 g/mol, and POE to a polymer of any molecular mass. PEG and
PEO are liquids or low-melting solids, depending on their molecular
weights. PEGs are prepared by polymerization of ethylene oxide and
are commercially available over a wide range of molecular weights
from 300 g/mol to 10,000,000 g/mol. While PEG and PEO with
different molecular weights find use in different applications, and
have different physical properties (e.g. viscosity) due to chain
length effects, their chemical properties are nearly identical.
Different forms of PEG are also available, depending on the
initiator used for the polymerization process--the most common
initiator is a monofunctional methyl ether PEG, or
methoxypoly(ethylene glycol), abbreviated mPEG.
Lower-molecular-weight PEGs are also available as purer oligomers,
referred to as monodisperse, uniform, or discrete PEGs are also
available with different geometries.
[0072] As used herein, the term PEG is intended to be inclusive and
not exclusive. The term PEG includes poly(ethylene glycol) in any
of its forms, including alkoxy PEG, difunctional PEG, multiarmed
PEG, forked PEG, branched PEG, pendent PEG (i.e., PEG or related
polymers having one or more functional groups pendent to the
polymer backbone), or PEG With degradable linkages therein.
Further, the PEG backbone can be linear or branched. Branched
polymer backbones are generally known in the art. Typically, a
branched polymer has a central branch core moiety and a plurality
of linear polymer chains linked to the central branch core. PEG is
commonly used in branched forms that can be prepared by addition of
ethylene oxide to various polyols, such as glycerol,
pentaerythritol and sorbitol. The central branch moiety can also be
derived from several amino acids, such as lysine. The branched
poly(ethylene glycol) can be represented in general form as
R(-PEG-OH)m in which R represents the core moiety, such as glycerol
or pentaerythritol, and m represents the number of arms.
Multi-armed PEG molecules, such as those described in U.S. Pat. No.
5,932,462, which is incorporated by reference herein in its
entirety, can also be used as biocompatible polymers.
[0073] Some exemplary PEGs include, but are not limited to, PEG20,
PEG30, PEG40, PEG60, PEG80, PEG100, PEG115, PEG200, PEG300, PEG400.
PEG500, PEG600, PEG1000, PEG1500, PEG2000, PEG3350, PEG4000,
PEG4600, PEG5000, PEG6000, PEG8000, PEG11000, PEG12000, PEG15000,
PEG20000, PEG250000, PEG500000, PEG100000, PEG2000000 and the like.
In some embodiments, PEG is of MW 10,000 Dalton. In some
embodiments, PEG is of MW 100,000, i.e. PEO of MW 100,000.
[0074] In some embodiments, the polymer is a biodegradable polymer.
As used herein, the term "biodegradable" describes a material which
can decompose under physiological conditions into breakdown
products. Such physiological conditions include, for example,
hydrolysis (decomposition via hydrolytic cleavage), enzymatic
catalysis (enzymatic degradation), and mechanical interactions. As
used herein, the term "biodegradable" also encompasses the term
"bioresorbable", which describes a substance that decomposes under
physiological conditions to break down to products that undergo
bioresorption into the host-organism, namely, become metabolites of
the biochemical systems of the host organism. As used herein, the
terms "bioresorbable" and "bioresorption" encompass processes such
as cell-mediated degradation, enzymatic degradation and/or
hydrolytic degradation of the bioresorbable polymer, and/or
elimination of the bioresorbable polymer from living tissue as will
be appreciated by the person skilled in the art.
[0075] The term "biodegradable polymer", as used herein, refers to
a polymer that at least a portion thereof decomposes under
physiological conditions. The polymer can thus be partially
decomposed or fully decomposed under physiological conditions.
Exemplary biodegradable polymers include, but are not limited to,
polyanhydrides, polyhydroxybutyric acid, polyorthoesters,
polysiloxanes, polycaprolactone, poly(lactic-co-glycolic acid),
poly(lactic acid), poly(glycolic acid), and copolymers prepared
from the monomers of these polymers.
[0076] In some embodiments, the additive comprises a bioinert
material. As used herein, the term "bioinert" refers to any
material that once placed in vivo has minimal interaction with its
surrounding tissue. Exemplary bioinert materials include, but are
not limited to, gold, stainless steel, titanium, alumina, partially
stabilized zirconia, and ultra-high molecular weight
polyethylene.
[0077] In some embodiments, the additive can be selected from the
group consisting of polyethylene oxide (PEO), polyethylene glycol
(PEG), collagen, fibronectin, keratin, polyaspartic acid,
polylysine, alginate, chitosan, chitin, hyaluronic acid, pectin,
polycaprolactone, polylactic acid, polyglycolic acid,
polyhydroxyalkanoates, dextrans, polyanhydrides, and any
combinations thereof.
[0078] In some embodiments, the additive can be a silk fibroin
particle or powder. Various methods of producing silk fibroin
particles (e.g., nanoparticles and microparticles) are known in the
art. See for example, PCT Publication No. WO 2011/041395 and No. WO
2008/118133; U.S. App. Pub. No. U.S. 2010/0028451; U.S. Provisional
Application Ser. No. 61/719,146, filed Oct. 26, 2012; and Wenk et
al. J Control Release, Silk fibroin spheres as a platform for
controlled drug delivery, 2008; 132: 26-34, content of all of which
is incorporated herein by reference in their entirety.
[0079] In some embodiments, the additive is a silk fibroin fiber.
In some embodiments, silk fibroin fibers could be chemically
attached by redissolving part of the fiber in HFIP and attaching to
stent. Use of silk fibroin fibers is described in, for example, US
patent application publication no. US20110046686, content of which
is incorporated herein by reference.
[0080] In some embodiments, the silk fibroin fibers are microfibers
or nanofibers. In some embodiments, the additive is micron-sized
silk fibroin fiber (10-600 .mu.m). Micron-sized silk fibroin fibers
can be obtained by hydrolyzing the degummed silk fibroin or by
increasing the boing time of the degumming process. Alkali
hydrolysis of silk fibroin to obtain micron-sized silk fibroin
fibers is described for example in Mandal et al., PNAS, 2012, doi:
10.1073/pnas. 1119474109; U.S. Provisional Application No.
61/621,209, filed Apr. 6, 2012; and PCT application no.
PCT/US13/35389, filed Apr. 5, 2013, content of all of which is
incorporated herein by reference. Because regenerated silk fibroin
fibers made from HFIP silk fibroin solutions are mechanically
strong, the regenerated silk fibroin fibers can also be used as
additive.
[0081] In some embodiments, the silk fibroin fiber is an
unprocessed silk fibroin fiber e.g., raw silk fibroin or raw silk
fibroin fiber. The term "raw silk fibroin" or "raw silk fibroin
fiber" refers to silk fibroin fiber that has not been treated to
remove sericin, and thus encompasses, for example, silk fibroin
fibers taken directly from a cocoon Thus, by unprocessed silk
fibroin fiber is meant silk fibroin, obtained directly from the
silk fibroin gland. When silk fibroin, obtained directly from the
silk fibroin gland, is allowed to dry, the structure is referred to
as silk fibroin I in the solid state. Thus, an unprocessed silk
fibroin fiber comprises silk fibroin mostly in the silk fibroin I
conformation. A regenerated or processed silk fibroin fiber on the
other hand comprises silk fibroin having a substantial silk fibroin
II or beta-sheet crystallinity.
[0082] Biologically Active Agents
[0083] In some embodiment, the bulk material of the anastomosis
device can comprise a biologically active agent. As used herein,
the term "biological activity" or "bioactivity" refers to the
ability of a molecule or composition to affect a biological sample.
Biological activity can include, without limitation, elicitation of
a stimulatory, inhibitory, regulatory, toxic or lethal response in
a biological assay. For example, a biological activity can refer to
the ability of a compound to modulate the effect/activity of an
enzyme, block a receptor, stimulate a receptor, modulate the
expression level of one or more genes, modulate cell proliferation,
modulate cell division, modulate cell morphology, or any
combination thereof. In some instances, a biological activity can
refer to the ability of a compound to produce a toxic effect in a
biological sample. The bulk material of the anastomosis device
containing the active agent can be formulated by mixing one or more
active agents with the silk fibroin-fibroin solution used to make
the stent.
[0084] Without limitations, the active agent can be selected from
small organic or inorganic molecules; saccharines;
oligosaccharides; polysaccharides; biological macromolecules;
peptides; proteins; peptide analogs and derivatives;
peptidomimetics; antibodies and antigen binding fragments thereof;
nucleic acids; nucleic acid analogs and derivatives; glycogens or
other sugars; immunogens; antigens; an extract made from biological
materials such as bacteria, plants, fungi, or animal cells; animal
tissues; naturally occurring or synthetic compositions; and any
combinations thereof. The active agent can be hydrophobic,
hydrophilic, or amphiphilic.
[0085] As used herein, the term "small molecule" can refer to
compounds that are "natural product-like," however, the term "small
molecule" is not limited to "natural product-like" compounds.
Rather, a small molecule is typically characterized in that it
contains several carbon-carbon bonds, and has a molecular weight of
less than 5000 Daltons (5 kD), preferably less than 3 kD, still
more preferably less than 2 kD, and most preferably less than 1 kD.
In some cases it is highly preferred that a small molecule have a
molecular mass equal to or less than 700 Daltons.
[0086] Total amount of active agent in the bulk material can be
from about 0.1 wt % to about 0.99 wt %, from about 0.1 wt % to
about 70 wt %, from about 5 wt % to about 60 wt %, from about 10 wt
% to about 50 wt %, from about 15 wt % to about 45 wt %, or from
about 20 wt % to about 40 wt %, of the total weight of the bulk
material.
[0087] Without wishing to be bound by a theory, the active agent
can be covalently or non-covalently associated with the bulk
material. In some embodiments, the active agent is distributed
homogenously in the bulk material, e.g., silk fibroin matrix. In
some embodiments, the active agent is absorbed/adsorbed on a
surface of the stent.
[0088] Examples of biologically active compounds include, but are
not limited to: cell attachment mediators, such as collagen,
elastin, fibronectin, vitronectin, laminin, proteoglycans, or
peptides containing known integrin binding domains e.g. "RGD"
integrin binding sequence, or variations thereof, that are known to
affect cellular attachment (Schaffner P & Dard, Cell Mol Life
Sci., 2003, 60(1):119-32 and Hersel U. et al., Biomaterials, 2003,
24(24):4385-415); YIGSR peptides; biologically active ligands; and
substances that enhance or exclude particular varieties of cellular
or tissue ingrowth.
[0089] In some embodiments, the active agent is a growth factor or
cytokine. A non-limiting list of growth factors and cytokines
includes, but is not limited, to stem cell factor (SCF),
granulocyte-colony stimulating factor (G-CSF),
granulocyte-macrophage stimulating factor (GM-CSF), stromal
cell-derived factor-1, steel factor, VEGF, TGF.beta., platelet
derived growth factor (PDGF), angiopoeitins (Ang), epidermal growth
factor (EGF), bFGF, HNF, NGF, bone morphogenic protein (BMP),
fibroblast growth factor (FGF), hepatocye growth factor,
insulin-like growth factor (IGF-1), interleukin (IL)-3,
IL-1.alpha., IL-1.beta., IL-6, IL-7, IL-8, IL-11, and IL-13,
colony-stimulating factors, thrombopoietin, ecrythropoietin,
fit3-ligand, and tumor necrosis factors (TNF.alpha. and TNF.beta.).
Other examples are described in Dijke et al., "Growth Factors for
Wound Healing", Bio/Technology, 7:793-798 (1989); Mulder G D,
Haberer P A, Jeter K F, eds. Clinicians' Pocket Guide to Chronic
Wound Repair. 4th ed. Springhouse, PA: Springhouse Corporation;
1998:85; Ziegler T. R., Pierce, G. F., and Herndon, D. N., 1997,
International Symposium on Growth Factors and Wound Healing: Basic
Science & Potential Clinical Applications (Boston, 1995, Serono
Symposia USA), Publisher Springer Verlag.
[0090] In some embodiments, the active agent can be selected from
anti-infectives such as antibiotics and antiviral agents;
chemotherapeutic agents (i.e. anticancer agents); anti-rejection
agents; anti-proliferative agents; analgesics and analgesic
combinations; anti-inflammatory agents; erythropoietin (EPO);
interferon .alpha. and .gamma.; interleukins; tumor necrosis factor
.alpha. and .beta.; insulin, antibiotics; adenosine; cytokines;
integrins; selectins; cadherins; insulin; hormones such as
steroids; cytotoxins; prodrugs; immunogens; or lipoproteins.
[0091] In some embodiments, the active agent is a therapeutic
agent. As used herein, the term "therapeutic agent" refers to a
biological or chemical agent used for treating, curing, mitigating,
or preventing deleterious conditions in a subject. The term
"therapeutic agent" also includes substances and agents for
combating a disease, condition, or disorder of a subject, and
includes drugs, diagnostics, and instrumentation. "Therapeutic
agent" also includes anything used in medical diagnosis, or in
restoring, correcting, or modifying physiological functions. The
terms "therapeutic agent" and "pharmaceutically active agent" are
used interchangeably herein.
[0092] The therapeutic agent is selected according to the treatment
objective and biological action desired. General classes of
therapeutic agents include anti-microbial agents such as adrenergic
agents, antibiotic agents or antibacterial agents, antiviral
agents, anthelmintic agents, anti-inflammatory agents,
antineoplastic agents, antioxidant agents, biological reaction
inhibitors, botulinum toxin agents, chemotherapy agents, diagnostic
agents, gene therapy agents, hormonal agents, mucolytic agents,
radioprotective agents, radioactive agents including brachytherapy
materials, tissue growth inhibitors, tissue growth enhancers, and
vasoactive agents. The therapeutic agent can be selected from any
class suitable for the therapeutic objective. For example, if the
objective is treating a disease or condition associated narrowing
in a blood vessel or other tubular organ or structure, the
therapeutic agent can include antithrombotic or fibrinolytic
agents.
[0093] Exemplary pharmaceutically active compound include, but are
not limited to, those found in Harrison's Principles of Internal
Medicine, 13th Edition, Eds. T. R. Harrison et al. McGraw-Hill
N.Y., NY; Physicians' Desk Reference, 50th Edition, 1997, Oradell
New Jersey, Medical Economics Co.; Pharmacological Basis of
Therapeutics, 8th Edition, Goodman and Gilman, 1990; United States
Pharmacopeia, The National Formulary, USP XII NF XVII, 1990;
current edition of Goodman and Oilman's The Pharmacological Basis
of Therapeutics; and current edition of The Merck Index, the
complete content of all of which are herein incorporated in its
entirety.
[0094] In some embodiments, the therapeutic agent can be selected
from the group consisting of anti-infectives, chemotherapeutic
agents, anti-rejection agents, analgesics and analgesic
combinations, anti-inflammatory agents, hormones, growth factors,
antibiotics, antiviral agents, steroids, bone morphogenic proteins,
bone morphogenic-like proteins, epidermal growth factor, fibroblast
growth factor, platelet derived growth factor (PDGF), insulin-like
growth factor, transforming growth factors, vascular endothelial
growth factor, and any combinations thereof.
[0095] In some embodiments, the therapeutic agent is an
antithrombotic or fibrinolytic agent selected from the group
consisting of anticoagulants, anticoagulant antagonists,
antiplatelet agents, thrombolytic agents, thrombolytic agent
antagonists, and any combinations thereof.
[0096] In some embodiments, the therapeutic agent is thrombogenic
agent selected from the group consisting of thrombolytic agent
antagonists, anticoagulant antagonists, pro-coagulant enzymes,
pro-coagulant proteins, and any combinations thereof. Some
exemplary thrombogenic agents include, but are not limited to,
protamines, vitamin K1, amiocaproic acid (amicar), tranexamic acid
(amstat), anagrelide, argatroban, cilstazol, daltroban,
defibrotide, enoxaparin, fraxiparine, indobufen, lamoparan,
ozagrel, picotamide, plafibride, tedelparin, ticlopidine,
triflusal, collagen, and collagen-coated particles.
[0097] In some embodiments, the therapeutic agent is a vasodilator.
A vasodilator can be selected from the group consisting of
alpha-adrenoceptor antagonists (alpha-blockers), agiotensin
converting enzyme (ACE) inhibitors, angiotensin receptor blockers
(ARBs), beta2-adrenoceptor agonists (.beta.2-agonists),
calcium-channel blockers (CCBs), centrally acting sympatholytics,
direct acting vasodilators, endothelin receptor antagonists,
ganglionic blockers, nitrodilators, phosphodiesterase inhibitors,
potassium-channel openers, renin inhibitors, and any combinations
thereof. Exemplary vasodilator include, but are not limited to,
prazosin, terazosin, doxazosin, trimazosin, phentolamine,
phenoxybenzamine, benazepril, captopril, enalapril, fosinopril,
lisinopril, moexipril, quinapril, ramipril, candesartan,
eprosartan, irbesartan, losartan, olmesartan, telmisartan,
valsartan, Epinephrine, Norepinephrine, Dopamine, Dobutamine,
Isoproterenol, amlodipine, felodipine, isradipine, nicalrdipine,
nifedipine, nimodipine, nitrendipine, clonidine, guanabenz,
guanfacine, .alpha.-methyldopa, hydralazine, Bosentan, trimethaphan
camsylate, isosorbide dinitrate, isosorbide mononitrate,
nitroglycerin, erythrityl tetranitrate, pentaerythritol
tetranitrate, sodium nitroprusside, milrinone, inamrinone (formerly
amrinone), cilostazol, sildenafil, tadalafil, minoxidil, aliskiren,
and analogs, derivatives, prodrugs, and pharmaceutically acceptable
salts thereof.
[0098] In some embodiments, the active agent is an anti-restenosis
or restenosis inhibiting agent. Suitable anti-restenosis agents
include: (1) antiplatelet agents including: (a) thrombin inhibitors
and receptor antagonists, (b) adenosine disphosphate (ADP) receptor
antagonists (also known as purinoceptor.sub.1 receptor
antagonists), (c) thromboxane inhibitors and receptor antagonists
and (d) platelet membrane glycoprotein receptor antagonists; (2)
inhibitors of cell adhesion molecules, including (a) selectin
inhibitors and (b) integrin inhibitors; (3) anti-chemotactic
agents; (4) interleukin receptor antagonists (which also serve as
anti-pain/anti-inflammation agents); and (5) intracellular
signaling inhibitors including: (a) protein kinase C (PKC)
inhibitors and protein tyrosine kinase inhibitors, (b) modulators
of intracellular protein tyrosine phosphatases, (c) inhibitors of
src homology.sub.2 (SH2) domains, and (d) calcium channel
antagonists. Exemplary specific restenosis-inhibiting agents
include microtubule stabilizing agents such as rapamycin, mitomycin
C, TAXOL.RTM., paclitaxel (I.e., paclitaxel, paxlitaxel analogs, or
paclitaxel derivatives, and mixtures thereof). For example,
derivatives suitable for use in the anastomosis device include
2'-succinyl-taxol, 2'-succinyl-taxol triethanolamine,
2'-glutaryl-taxol, 2'-glutaryl-taxol triethanolamine salt,
2'-O-ester with N-(dimethylaminoethyl) glutamine, and 2'-O-ester
with N-(dimethylaminoethyl) glutamide hydrochloride salt.
[0099] In some embodiments, the active agent is an anti-coagulation
agent. As used herein, the term "anti-coagulation agent" refers to
any molecule or composition that promotes blood coagulation or
activates the blood coagulation cascade or a portion thereof.
Exemplary anti-coagulation agents include, for example,
phospholipids such as, e.g., negatively charged phospholipids;
lipoproteins such as, e.g., thromboplastin, and the like; proteins
such as tissue factor, activated serin proteases such as Factors
IIa (thrombin), VII, VIIa, VIII, IX, IXa, Xa, XIa, XII, XIIa, von
Willebrand factor (vWF), protein C, snake venoms such as
PROTAC.RTM. enzyme, Ecarin, Textarin, Noscarin, Batroxobin,
Thrombocytin, Russell's viper venom (RVV), and the like; polyvalent
cations; calcium ions; tissue factor, silica; kaolin; bentonite;
diatomaceous earth; ellagic acid; celitc; and any mixtures
thereof.
[0100] In some embodiments, the agent is a nitric oxide or a
prodrug thereof.
[0101] Without wishing to be bound by a theory, incorporating an
active agent in the bulk material of the anastomosis device enables
the delivery of active agent in a controlled released manner.
Maintaining the active agent in an active form throughout the
process of incorporating the agent in the silk fibroin-fibroin
matrix enables it to be active upon release from the stent.
Controlled release of the active agent permits active agent to be
released sustainably over time, with controlled release kinetics.
In some instances, the active agent is delivered continuously to
the site where treatment is needed, for example, over several
weeks. Controlled release over time, for example, over several days
or weeks, or longer, permits continuous delivery of the bioactive
agent to obtain preferred treatments. The controlled delivery is
advantageous because it protects the bioactive agent from
degradation in vivo in body fluids and tissue, for example, by
proteases.
[0102] Controlled release of the active agent from the anastomosis
device can be designed to occur over time, for example, over 12
hours or 24 hours. The time of release may be selected, for
example, to occur over a time period of about 12 hours to 24 hours;
about 12 hours to 42 hours; or, e.g., about 12 to 72 hours. In
another embodiment, release can occur for example on the order of
about 1 day to 15 days. The controlled release time can be selected
based on the condition treated. For example, longer times can be
more effective for wound healing, whereas shorter delivery times
can be more useful for some cardiovascular applications.
[0103] Controlled release of the active agent from the anastomosis
device in vive can occur, for example, in the amount of about 1 ng
to 1 mg/day. In other embodiments, the controlled release can occur
in the amount of about 50 ng to 500 ng/day, about 75 ng to 250
ng/day, about 100 ng to 200 ng/day, or about 125 ng to 175
ng/day.
[0104] In some embodiments, the active agent is an enzyme that
hydrolyzes silk fibroin. Without wishing to be bound by a theory,
such enzymes can be used to control the degradation of the
anastomosis device after implantation into a subject. Controlled
degradation of silk fibroin-fibroin based scaffolds with enzymes
embedded therein is described in, for example, U.S. Provisional
Application No. 61/791,501, filed Mar. 15, 2013, content of which
is incorporated herein by reference in its entirety.
[0105] Cells
[0106] In some embodiments, the bulk material of the anastomosis
device can comprise a cell. Anastomosis device with the bulk
material comprising a cell can be used for organ repair, organ
replacement or regeneration. Cells amenable to be incorporated into
the composition include, but are not limited to, stem cells
(embryonic stem cells, mesenchymal stem cells, neural stem cells,
bone-marrow derived stem cells, hematopoietic stem cells, and
induced pluripotent stem cells); pluripotent cells; chondrocytes
progenitor cells; pancreatic progenitor cells; myoblasts;
fibroblasts; chondrocytes; keratinocytes; neuronal cells; glial
cells; astrocytes; pre-adipocytes; adipocytes; vascular endothelial
cells; hair follicular stem cells; endothelial progenitor cells;
mesenchymal cells; smooth muscle progenitor cells; osteocytes;
parenchymal cells such as hepatocytes; pancreatic cells (including
Islet cells); cells of intestinal origin; and combination thereof,
either as obtained from donors, from established cell culture
lines, or even before or after molecular genetic engineering.
Without limitations, the cells useful for incorporation into the
composition can come from any source, for example human, rat or
mouse. In some embodiments, the cell can from a subject into which
the anastomosis device is to be implanted.
[0107] In some embodiments, the cell is a genetically modified
cell. A cell can be genetically modified to express and secrete a
desired compound, e.g. a bioactive agent, a growth factor,
differentiation factor, cytokines, and the like. Methods of
genetically modifying cells for expressing and secreting compounds
of interest are known in the art and easily adaptable by one of
skill in the art.
[0108] Differentiated cells that have been reprogrammed into stem
cells can also be used. For example, human skin cells reprogrammed
into embryonic stem cells by the transduction of Oct3/4, Sox2,
c-Myc and Klf4 (Junying Yu, et. al., Science, 2007, 318, 1917-1920
and Takahashi K. et. al., Cell, 2007, 131, 1-12).
[0109] When using a anasomosis device with cells, it can be
desirable to add other materials to promote the growth,
differentiation or proliferation of the cell. Exemplary materials
known to promote cell growth include, but not limited to, cell
growth media, such as Dulbecco's Modified Eagle Medium (DMEM),
fetal bovine serum (FBS), non-essential amino acids and
antibiotics, and growth and morphogenic factors such as fibroblast
growth factor (e.g., FGF 1-9), transforming growth factors (TGFs),
vascular endothelial growth factor (VEGF), epidermal growth factor
(EGF), platelet derived growth factor (PDGF), insulin-like growth
factor (IGF-I and IGF-II), bone morphogenetic growth factors (e.g.,
BMPs 1-7), bone morphogenetic-like proteins (e.g., GFD-5, GFD-7,
and GFD-8), transforming growth factors (e.g., TGF-.alpha.,
TGF-.beta. I-III), nerve growth factors, and related proteins.
Growth factors are known in the art, see. e.g., Rosen & Thies,
CELLULAR & MOL. BASIS BONE FORMATION & REPAIR (R. G. Landes
Co.).
[0110] Material Properties and Modification
[0111] Crystallinity
[0112] Optionally, the conformation of the silk fibroin in the
anastomosis device can be altered before, during or after formation
of the device. The induced conformational change alters the
crystallinity of the silk fibroin, e.g., Silk fibroin II beta-sheet
crystallinity. Without wishing to be bound by a theory, it is
believed that degradation of the bulk material or optional release
of an additive (e.g., an active agent) from the bulk material
varies with the beta-sheet content of the silk fibroin. The
conformational change can be induced by any methods known in the
art, including, but not limited to, alcohol immersion (e.g.,
ethanol, methanol), water annealing, shear stress (e.g., by
vortexing), ultrasound (e.g., by sonication), pH reduction (e.g.,
pH titration and/or exposure to an electric field) and any
combinations thereof. For example, the conformational change can be
induced by one or more methods, including but not limited to,
controlled slow drying (Lu et al., 10 Biomacromolecules 1032
(2009)); water annealing (Jin et al., Water-Stable Silk fibroin
Films with Reduced .beta.-Sheet Content, 15 Adv. Funct. Mats. 1241
(2005); Hu et al. Regulation of Silk fibroin Material Structure by
Temperature-Controlled Water Vapor Annealing, 12 Biomacromolecules
1686 (2011)); stretching (Demura & Asakura, Immobilization of
glucose oxidase with Bombyx mori silk fibroin by only stretching
treatment and its application to glucose sensor, 33 Biotech &
Bioengin. 598 (1989)); compressing; solvent immersion, including
methanol (Hofmann et al., Silk fibroin as an organic polymer for
controlled drug delivery, 111 J Control Release. 219 (2006)),
ethanol (Miyairi et al., Properties of b-glucosidase immobilized in
sericin membrane. 56 J. Fermen. Tech. 303 (1978)), glutaraldehyde
(Acharya et al., Performance evaluation of a silk fibroin
protein-based matrix for the enzymatic conversion of tyrosine to
L-DOPA. 3 Biotechnol J. 226 (2008)), and 1-ethyl-3-(3-dimethyl
aminopropyl) carbodiimide (EDC) (Bayraktar et al., Silk fibroin as
a novel coating material for controlled release of theophylline. 60
Eur J Pharm Biopharm. 373 (2005)); pH adjustment, e.g., pH
titration and/or exposure to an electric field (see, e.g., U.S.
Patent App. No. US2011/0171239); heat treatment; shear stress (see,
e.g., International App. No.: WO 2011/005381), ultrasound, e.g.,
sonication (see, e.g., U.S. Patent Application Publication No. U.S.
2010/0178304 and International App. No. WO2008/150861); and any
combinations thereof. Content of all of the references listed above
is incorporated herein by reference in their entirety.
[0113] In some embodiments, the conformation of the silk fibroin
can be altered by water annealing. Without wishing to be bound by a
theory, it is believed that physical temperature-controlled water
vapor annealing (TCWVA) provides a simple and effective method to
obtain refined control of the molecular structure of silk fibroin
biomaterials. The silk fibroin materials can be prepared with
control of crystallinity, from a low content, using conditions at
4.degree. C. (.alpha. helix (alpha-helix) dominated silk fibroin I
structure), to highest content of .about.60% crystallinity at
100.degree. C. (.beta.-sheet (beta-sheet) dominated silk fibroin II
structure). This physical approach covers the range of structures
previously reported to govern crystallization during the
fabrication of silk fibroin materials, yet offers a simpler, green
chemistry, approach with tight control of reproducibility.
Temperature controlled water vapor annealing is described, for
example, in Hu et al., Regulation of Silk fibroin Material
Structure By Temperature Controlled Water Vapor Annealing,
Biomacromolecules, 2011, 12(5): 1686-1696, content of which is
incorporated herein by reference in its entirety.
[0114] In some embodiments, alteration in the conformation of the
silk fibroin can be induced by immersing in alcohol, e.g.,
methanol, ethanol, etc. The alcohol concentration can be at least
10%, at least 20%, at least 30%, at least 40%, at least 50%, at
least 60%, at least 70%, at least 80%, at least 90% or 100%. In
some embodiment, alcohol concentration is 100%. If the alteration
in the conformation is by immersing in a solvent, the silk fibroin
composition can be washed, e.g., with solvent/water gradient to
remove any of the residual solvent that is used for the immersion.
The washing can be repeated one, e.g., one, two, three, four, five,
or more times.
[0115] In some embodiments, the alteration in the conformation of
the silk fibroin can be induced with sheer stress. The sheer stress
can be applied, for example, by passing the silk fibroin
composition through a needle. Other methods of inducing
conformational changes include applying an electric field, applying
pressure, or changing the salt concentration.
[0116] The treatment time for inducing the conformational change
can be any period of time to provide a desired silk fibroin II
(beta-sheet crystallinity) content. In some embodiments, the
treatment time can range from about 1 hour to about 12 hours, from
about 1 hour to about 6 hours, from about 1 hour to about 5 hours,
from about 1 hour to about 4 hours, or from about 1 hour to about 3
hours. In some embodiments, the sintering time can range from about
2 hours to about 4 hours or from 2.5 hours to about 3.5 hours.
[0117] When inducing the conformational change is by solvent
immersion, treatment time can range from minutes to hours. For
example, immersion in the solvent can be for a period of at least
about 15 minutes, at least about 30 minutes, at least about 1 hour,
at least about 2 hours, at least 3 hours, at least about 6 hours,
at least about 18 hours, at least about 12 hours, at least about 1
day, at least about 2 days, at least about 3 days, at least about 4
days, at least about 5 days, at least about 6 days, at least about
7 days, at least about 8 days, at least about 9 days, at least
about 10 days, at least about 11 days, at least about 12 days, at
least about 13 days, or at least about 14 days. In some
embodiments, immersion in the solvent can be for a period of about
12 hours to about seven days, about 1 day to about 6 days, about 2
to about 5 days, or about 3 to about 4 days. In one embodiment,
immersion in the solvent can be for a period of about minutes.
[0118] Without limitations, the silk fibroin in the anastomosis
device can comprise a silk fibroin II beta-sheet crystallinity
content of at least about 5%, at least about 10%, at least about
20%, at least about 30%, at least about 40%, at least about 50%, at
least about 60%, at least about 70%, at least about 80%, at least
about 90%, or at least about 95% but not 100% (i.e., all the silk
fibroin is present in a silk fibroin II beta-sheet conformation).
In some embodiments, silk fibroin in the anastomosis device is
present completely in a silk fibroin II beta-sheet conformation,
i.e., 100% silk fibroin II beta-sheet crystallinity.
Porosity
[0119] To improve controlled endothelialization and remodeling of
the anastomosis device, the wall formulation can be modified to
incorporate finely tuned nano- or micro-porosities. Without wishing
to be bound by a theory, nano-porosity in the wall of the vessel
anastomosis device can facilitate nutrient, oxygen, and waste
exchange improving natural vessel healing. The porosity can be
tuned in such a way that a controlled amount of fluid will be
diffused to allow this beneficial exchange without harmful loss
blood pressure or volume. Accordingly, in some embodiments, the
anastomosis device can be porous, i.e., the bulk material (e.g.,
wall of the device) can comprise pores, such as nanopores or
micropores.
[0120] For example, the bulk material of the anastomosis device can
have a porosity of at least about 10%, at least about 20%, at least
about 30%, at least about 40%, at least about 50%, at least about
60%, at least about 70%, at least about 80%, at least about 90%, or
higher. One of skill in the art can adjust the porosity
accordingly, based on a number of factors such as, but not limited
to, desired physical or mechanical properties of the stent, release
rates, molecular size and/or diffusion coefficient of the molecule
distributed in the bulk material, and/or concentrations, amounts of
silk fibroin in the bulk material. As used herein, the term
"porosity" is a measure of void spaces in a material and is a
fraction of volume of voids over the total volume, as a percentage
between 0 and 100% (or between 0 and 1). Determination of porosity
is well known to a skilled artisan, e.g., using standardized
techniques, such as mercury porosimetry and gas adsorption, e.g.,
nitrogen adsorption.
[0121] The pores can be of any desired pore size. As used herein,
the term "pore size" refers to a diameter or an effective diameter
of the cross-sections of the pores. The term "pore size" can also
refer to an average diameter or an average effective diameter of
the cross-sections of the pores, based on the measurements of a
plurality of pores. The effective diameter of a cross-section that
is not circular equals the diameter of a circular cross-section
that has the same cross-sectional area as that of the non-circular
cross-section. In some embodiments, the pores can have a size
distribution ranging from about 50 nm to about 1000 .mu.m, from
about 250 nm to about 500 .mu.m, from about 500 nm to about 250
.mu.m, from about 1 .mu.m to about 200 .mu.m, from about 10 .mu.m
to about 150 .mu.m, or from about 50 .mu.m to about 100 .mu.m. In
some embodiments, the anastomosis device can be swellable when
hydrated. The sizes of the pores can then change depending on the
water content in the stent. In some embodiment, the pores can be
filled with a fluid such as water or air.
[0122] Methods for forming pores in silk fibroin-based scaffolds
are known in the art and include, but are not limited,
porogen-leaching methods, freeze-drying methods, and/or gas-forming
method. Exemplary methods for forming pores in a silk fibroin-based
material are described, for example, in U.S. Pat. App. Pub. Nos. US
2010/0279112 and US 2010/0279112; U.S. Pat. No. 7,842,780; and
WO2004062697, content of all of which is incorporated herein by
reference in its entirety.
[0123] FIG. 8A shows an embodiment of the porogen leaching method
for forming the pores. As shown, sodium chloride crystals (NaCl)
can be suspended in HFIP silk fibroin solution (5% to 20%) with the
final concentration of NaCl ranging from <10 mg/ml to >250
mg/ml. The silk fibroin/NaCl blend can be coated onto Teflon rods
of various diameters and dried completely. The silk fibroin/NaCl
tubes can then be stabilized in 100% methanol for 10 to 20 minutes
to induce beta-sheet crystallization of the silk fibroin. NaCl
crystals are then leached out in deionized water.
[0124] FIG. 9A shows an embodiment of forming pores using particles
as the porogen. As shown, poly(methyl methacrylate) (PMMA)
nano-spheres (of various controlled diameters) can be blended with
aqueous silk fibroin solution. The nano-spheres are spun down and
re-suspended in an aqueous silk fibroin solution. The final
concentration of nano-spheres in silk fibroin solution can be 1% or
greater. To ensure a porous luminal surface of the device, PMMA
spheres suspended in deionized water, can be first coated on to the
rod surface followed by a coating of the silk fibroin/PMMA blend.
Several layers of the blended solution can then be coated onto the
Teflon rods as discussed above and dried. The silk fibroin/PMMA
dried tubes are then immersed in acetone solution (50%-100%) to
dissolve and leach out the PMMA spheres. The porous silk fibroin
tubes can then be stabilized in 100% methanol for 10 to 20 minutes
to induce beta-sheet crystallization of the silk fibroin and then
re-hydrated in deionized water.
[0125] Though not meant to be bound by a theory, a device's
porosity, structure, and mechanical properties can be controlled
via different post-spinning processes such as vapor annealing, heat
treatment, alcohol treatment, air-drying, lyophilization and the
like. Additionally, any desirable release rates, profiles or
kinetics of a molecule encapsulated in the anastomosis device can
be controlled by varying processing parameters, such as anastomosis
device thickness, silk fibroin molecular weight, concentration of
silk fibroin in the bulk material, beta-sheet conformation
structures, silk fibroin II beta-sheet crystallinity, or porosity
and pore sizes.
Construction
[0126] The cylindrical portion of an anastomosis device can be made
using any method known in the art for preparing a cylindrical silk
fibroin matrix, e.g., silk fibroin tube. For example, tubes can be
made using molding, dipping, electrospinning, gel spinning, and the
like. Gel spinning is described in Lovett et al. (Biomaterials,
29(35):4650-4657 (2008)) and the construction of gel-spun silk
fibroin tubes is described in PCT application no.
PCT/US2009/039870, filed Apr. 8, 2009, content of both of which is
incorporated herein by reference in their entirety. Construction of
silk fibroin tubes using the dip-coating method is described in PCT
application no. PCT/US2008/072742, filed Aug. 11, 2008, content of
which is incorporated herein by reference in its entirety.
Construction of silk fibroin tubes using the film-spinning method
is described in PCT application No. PCT/US2013/030206, filed Mar.
11, 2013 and U.S. Provisional application No. 61/613,185, filed
Mar. 20, 2012, content of both of which is incorporated herein by
reference.
[0127] A number of different methods can be used to fabricate an
anastomosis devices and/or components; for example, anastomosis
devices can be prepared from bulk material solution using a number
of different methods. In some embodiments, after fabrication, these
components can be annealed in a humid environment for 6 hours at
80.degree. C., to induce .beta.-sheet formation, increase the mesh
crystallinity and thereby improve mesh mechanical properties,
resiliency, and water insolubility. Alternatively, following
published protocols [3], silk fibroin components can be submerged
in 99.9% (w/v) methanol for 5 minutes to induce crystallinity.
[0128] The device according to an embodiment of FIG. 1 can be
fabricated by coating extruded dextrose rods with HFIP silk fibroin
solution. Dextrose is caramelized then brought to a stable
temperature of 105.degree. F. Mechanical drawing of sugar rods can
be controlled with stepper motors to increase consistency and
repeatability. Rods can be fine-drawn to a diameter of 100 to 1000
.mu.m as desired. Dextrose rods can be coated in silk fibroin
solubilized in HFIP solution, e.g., 17% silk fibroin (w/v) solution
in HFIP. Silk fibroin coating is crystallized via submersion in
methanol or water annealing. Dextrose is leached in water, leaving
a small diameter hollow silk fibroin tube. These tubes can be
removed and sectioned to desired length, and each end can be
beveled 45.degree..
[0129] The device according to an embodiment of FIG. 2 can be
fabricated by dip-coating Teflon coated stainless steel rods. For
example, Teflon coated stainless steel rods (650 to 4500 .mu.m
diameter) which increase in diameter by 250 .mu.m can be dipped
into aqueous silk fibroin:glycerol solution and allowed to dry
producing a tubular film layer of application specific target
thickness (e.g., 150 to 300 .mu.m) which can be measured using a
micrometer. The spherical tips which facilitate security and
sealing of the anastomosis can be produced as compliant silk
fibroin beads in a separate step. Beads can be produced on separate
rods with diameter equivalent to the OD of the silk fibroin coated
rods. Rods can be rotated using a modified lathe to ensure
concentric spherical shape. Volumes (5 to 50 .mu.L) of silk fibroin
solution can be dispensed using a multichannel pipette onto the
rotating rods such that they result in required bead size. Beads
can be designed to have an outer diameter equivalent to 125% of the
coated tube outer diameter. After depositing the beads on rotating
rods, they can be placed in methanol before complete drying into
film. This induces crystallization of the silk fibroin solution
which leads to gelation into resilient beads which can then be
removed and placed at appropriate distances around the coated
tubes. They can be fixed in location using silk fibroin solution as
an adhesive, and then crystallized by submerging in methanol
forming a permanent bond. These tubes can be removed and sectioned
to desired length.
[0130] The device according to an embodiment of FIG. 3 can be
fabricated by separately fabricating a tubular component with
microneedles protruding outward at one end and a tubular
sheath.
[0131] The tubular component tubular component with microneedles
protruding outward at one end can be fabricated by coating
stainless steel rods (e.g., 650 to 4500 .mu.m diameter) with
aqueous silk fibroin solution (e.g., a silk fibroin:glycerol
solution) and allowed to dry producing a tubular film layer of
desired thickness (e.g., 250 .mu.m) which can be measured using a
micrometer. The rows of silk fibroin microneedles can be added in a
second step by circumferentially bonding microneedle arrays. The
microneedle arrays can be produced by covering an epoxy mold with
silk fibroin solution then centrifuging into the mold to remove
air. The backing of the microneedle arrays can be coated with a
thin layer of aqueous silk fibroin solution (e.g., a silk
fibroin:glycerol solution) and then wrapped around the tubular
component. The arrays can be temporarily fixed circumferentially
using a malleable stainless wire and allowed to dry for a period of
time, e.g., for 24 hours. If present, glycerol stabilizes a
non-soluble conformation of the silk fibroin protein thereby
leaving a permanent non-soluble bond. The tubular sheath component
can be fabricated by coating stainless steel rods (equivalent in
diameter to the summed diameter of tubular component with
microneedles, including the microneedles, with an aqueous silk
fibroin solution (e.g., silk fibroin:glycerol solution) and allowed
to dry producing a tubular film layer of the desired thickness,
e.g. 150 .mu.m, which can be measured using a micrometer.
[0132] The device according to an embodiment of FIG. 5 can be
fabricated by separately fabricating the three different components
of the device. Part 1, a tubular component with several
circumferential rows of silk fibroin microneedles protruding
outward at each end, can be fabricated by coating stainless steel
rods (e.g., 650 to 4500 .mu.m diameter) with an aqueous silk
fibroin solution (e.g., a silk fibroin:glycerol solution) and
allowed to dry producing a tubular film layer of desired thickness
(e.g., 150 to 300 .mu.m thickness), which is measured using a
micrometer. These tubes can be removed and sectioned to desired
length. The rows of silk fibroin microneedles can be added in a
second step by circumferentially bonding microneedle arrays. The
microneedle arrays can be produced by covering an epoxy mold with
silk fibroin solution then centrifuging into the mold to remove
air. The backing of the microneedle arrays can be coated with a
thin layer of an aqueous silk fibroin solution (e.g., silk
fibroin:glycerol solution) then wrapped around each end of the
tubular component. The arrays can be temporarily fixed
circumferentially using a malleable stainless wire and allowed to
dry for a period of time, e.g., 24 hours. If present in the
solution, glycerol stabilizes a non-soluble conformation of the
silk fibroin protein thereby leaving a permanent non-soluble bond.
Part 2 and Part 3, tubular sheaths, can be fabricated by coating
stainless steel rods (equivalent in diameter to the summed diameter
of Part 1 including the microneedles) with an aqueous silk fibroin
solution (e.g., a silk fibroin:glycerol solution) and allowed to
dry producing a tubular film layer of the desired thickness (e.g.,
150 .mu.m thickness), which can be measured using a micrometer.
[0133] The device according to an embodiment of FIG. 6 can be
fabricated by separately fabricating the three different components
of the device. Part 1, a tubular with spherical barb tips at each
end, can be fabricated by coating stainless steel rods (e.g., 650
to 4500 .mu.m diameter) with an aqueous silk fibroin solution
(e.g., a silk fibroin:glycerol solution) and allowed to dry
producing a tubular film layer of application specific target
thickness (e.g., 150 to 300 .mu.m) which can be measured using a
micrometer. The spherical tips which facilitate security and
sealing of the anastomosis can be produced as compliant silk
fibroin beads in a separate step. Beads can be produced on separate
rods with diameter equivalent to the OD of the silk fibroin coated
rods. Rods can be rotated using a lathe to ensure concentric
spherical shape. Volumes (5 to 50 .mu.L) of silk fibroin solution
can be dispensed using a multichannel pipette onto the rotating
rods such that they result in required bead size. Beads can be
designed to have an outer diameter equivalent to 125% of the coated
tube outer diameter. After depositing the beads on rotating rods,
they can be placed in methanol before complete drying into film.
This induces crystallization of the silk fibroin solution which
leads to gelation into resilient beads which can then be removed
and placed at appropriate distances around the coated tubes. They
can be fixed in location using silk fibroin solution as an
adhesive, and then crystallized by submerging in methanol forming a
permanent bond. These tubes can be removed and sectioned to desired
length. Part 2 and Part 3, the helical sleeves, can be fabricated
by coating a helical silicone rod with an aqueous silk fibroin
solution (e.g., a silk fibroin:glycerol solution). The rod can be
composed of platinum cure silicone rubber measuring a shore
hardness of 10 A. The helical geometry can end in a cuff with an
inner radius matching the helical amplitude. After the silk fibroin
coating has dried, the rod diameter can be reduced by applying
tensile stress and the silk fibroin coating can be twisted down and
off of the silicone rod. The inner thread flank, of the helical,
sheath can progress to the thread root at a curvature matching the
exterior of the coupler end bead. The helical sheath can be
sectioned in half into two pieces, preserving the cuff on one
piece. The sectioned piece without the cuff is Part 2. The
sectioned piece with the cuff is Part 3.
Device Properties
[0134] An anastomosis device disclosed herein can comprise any
desired mechanical stiffness. For example, the anastomosis device
can comprise an average mechanical stiffness of about 0.01
kN/m.sup.2 to about 100 kN/m.sup.2. In some embodiments, the
anastomosis device can comprise an average mechanical stiffness of
from about 0.05 kN/m.sup.2 to about 75 kN/m.sup.2, from about 0.1
kN/m.sup.2 to about 50 kN/m.sup.2, from about 0.25 kN/m.sup.2 to
about 25 kN/m.sup.2, from about 0.5 kN/m.sup.2 to about 10
kN/m.sup.2, or from about 0.75 kN/m.sup.2 to about 2 kN/m.sup.2. In
one embodiment, the anastomosis device has an average mechanical
stiffness of about 1.2 kN/m.sup.2.
[0135] The radial strength of the anastomosis device can also be
optimized for any desired application. For example, the anastomosis
device can have an average radial strength of from about 100 mmHg
to about 1000 mmHg. In some embodiments, the anastomosis device has
an average radial strength of from about 75 mmHg to about 750 mmHg,
from about 50 mmHg to about 600 mmHg, from about 100 mmHg to about
500 mmHg, from about 150 mmHg to about 450 mmHg, from about 200
mmHg to about 450 mmHg, or from about 250 mmHg to about 350 mmHg.
In some embodiments, the anastomosis device has an average radial
strength of about 300 mmHg.
[0136] Compressive toughness is the capacity of a material to
resist fracture when subjected to axially directed pushing forces.
By definition, the compressive toughness of a material is the
ability to absorb mechanical (or kinetic) energy up to the point of
failure. Toughness is measured in units of joules per cubic meter
(Jm.sup.-3) and can be measured as the area under a stress-strain
curve. In some embodiments, the anastomosis device has a
compressive toughness of about 1 kJm.sup.-3 to about 20 kJm.sup.-3
or about 1 kJm.sup.-3 to about 5 kJm.sup.-3 at 6% strain as
measured by the J-integral method.
[0137] Compressive strength is the capacity of a material to
withstand axially directed pushing forces. By definition, the
compressive strength of a material is that value of uniaxial
compressive stress reached when the material fails completely. A
stress-strain curve is a graphical representation of the
relationship between stress derived from measuring the load applied
on the sample (measured in Pascals) and strain derived from
measuring the displacement as a result of compression of the
sample. The ultimate compressive strength of the material can
depend upon the target site of implantation. In some embodiments,
the anastomosis device comprise a compressive strength (stress to
yield point) of approximately 1 MPa to approximately 10 MPa.
[0138] Compressive elastic modulus is the mathematical description
of the tendency of a material to be deformed elastically (i.e.
non-permanently) when a force is applied to it. The Young's modulus
(E) describes tensile elasticity, or the tendency of a material to
deform along an axis when opposing forces are applied along that
axis; it is defined as the ratio of tensile stress to tensile
strain (measured in Pascals) and is otherwise known as a measure of
stiffness of the material. The elastic modulus of an object is
defined as the slope of the stress-strain curve in the elastic
deformation region. The anastomosis device can comprise a
compressive elastic modulus of between approximately 1 MPa and
approximately 30 MPa at 5% strain.
[0139] In some embodiments, the anastomosis device can be
bioresorbed after implantation into a subject. As used herein, the
term "bioresorbed" or "bioresorption" refers to infiltration of
endogenous tissue or cells into an implanted structure, e.g.,
stent, which permits integration of the implantable structure and
tissues, where one or more components of the implanted structure is
replaced by new tissue. For example, the anastomosis device can
degrade as tissue surrounding the target site remodels or
regenerates.
[0140] Crush resistance of five different implant wall thickness
are compared to a clinically available self-expanding metal stent
(Boston Scientific Wallstent.RTM.) in FIG. 10. As seen, the
collapse pressure increased with increasing wall thickness.
Multilayer Devices
[0141] In some embodiments, the cylindrical body portion of the
anastomosis device can be a multilayered cylindrical body portion.
If a multilayered anastomosis device comprises an additive and/or
active agent, different layers of the body can comprises same or
different additive or active agents. For example, some layers can
comprise a first additive (or active agent) and some other layers
can comprise a second additive (or active agent). In some
embodiments, the outermost layer comprises no active agent. The
number of layers in the multilayered cylindrical body portion of
the anastomosis device can be any desired number. For example, the
multilayered cylindrical body portion of the anastomosis device can
comprise from 1 to 100, 1 to 75, 1 to 50, 1 25, or 1 to 20
layers.
[0142] Without limitations, thickness of each layer can range
independently from nanometers to millimeters. For example,
thickness of layer can be 1 nm to 1000 nm, 1 nm to 500 nm, 1 nm to
250 nm, 1 nm to 100 nm, 1 nm to 50 nm, 1 nm to 25 nm, 1 nm to 10
nm, 1 .mu.m to 1000 .mu.m, 1 .mu.m to 500 .mu.m, 1 .mu.m to 250
.mu.m, 1 .mu.m to 100 .mu.m, 1 .mu.m to 50 .mu.m, or 1 .mu.m to 25
.mu.m.
[0143] Further all layers can be of the same thickness, all of
different thickness, or some of same and some of different
thickness.
Particular Embodiments and Features
[0144] The anastomosis device designs according to the present
invention can also incorporate other features of silk fibroin and
silk fibroin based polymers, including the ability to load and
deliver therapeutic compounds and up to 100% degradability of the
anastomosis device material over time within the body.
[0145] In accordance with some embodiments of the invention, the
bulk material can include a silk fibroin:glycerol blend in a dry
weight ratio of 75:25. The bulk material can be fabricated as
described below. Other plasticizers, in addition to or instead of
glycerol, can be used. Other weight ratios can also be used.
[0146] In accordance with some embodiments, the bulk silk fibroin
material can be formed from Cocoons of the silk fibroinworm Bombyx
mori (supplied by Tajima Shoji Co., Yokohama, Japan). Sodium
carbonate, lithium bromide, and Slide-a-Lyzer dialysis cassettes
can be purchased from Pierce, Inc. (Rockford, Ill., US). Silk
fibroin solutions can be prepared by processing the silk fibroin
cocoons. The B. mori silk fibroin cocoons can be boiled in 0.02M
aqueous Na.sub.2CO.sub.3 for 30 minutes to extract the sericin
component and isolate the silk fibroin protein. The isolated silk
fibroin can then be washed three times for 20 minutes in deionized
water and allowed to dry for 48 hours at room temperature. The
dried silk fibroin can be dissolved in 93M LiBr at 60.degree. C.
for 4 h, and the resulting 20% (w/v) solution can be dialyzed
against water using a Slide-a-Lyzer dialysis cassette (molecular
weight cutoff 3500) for two days to remove salts. The resulting
concentration of aqueous silk fibroin ranged from 5-7% (w/v), which
was calculated by weighing the remaining solid after drying. The
aqueous silk fibroin solution can be concentrated by exposing the
cassette membrane to ambient air for varying times to produce a
10-20% (w/v) silk fibroin aqueous solution. Deionized water can be
blended with the silk fibroin solutions to bring concentrations
below 5%. The silk fibroin solutions can be stored at 4.degree. C.
until use. Aqueous fibroin solution prepared as described above can
be used to cast sheet and tubular films as described above. The
films can be fabricated by blending aqueous fibroin with 99% (w/v)
glycerol to produce blends of 75:25 (dry weight) silk
fibroin:glycerol solution.
[0147] Other embodiments are within the scope and spirit of the
invention. Features implementing functions may also be physically
located at various positions, including being distributed such that
portions of functions are implemented at different physical
locations.
[0148] Further, while the description above refers to the
invention, the description may include more than one invention.
EXEMPLIFICATION
Example 1
Fabrication of Certain Exemplary Devices
[0149] Materials
[0150] Cocoons of the silkworm Bombyx mori were supplied by Tajima
Shoji Co. (Yokohama, Japan). Sodium carbonate, lithium bromide,
Slide-a-Lyzer dialysis cassettes were purchased from Pierce, Inc.
(Rockford, Ill., US).
[0151] Preparation of HFIP Silk Solutions
[0152] Silk fibroin solutions were prepared following published
procedures [1]. In brief, B. mori silk cocoons were boiled in 0.02M
aqueous Na.sub.2CO.sub.3 for 30 minutes to extract the sericin
component and isolate the silk fibroin protein. Isolated silk
fibroin was then washed three times for 20 minutes in deionized
water and allowed to dry for 48 hours at room temperature. Dried
silk was dissolved in 9.3M LiBr at 60.degree. C. for 4 h, and the
resulting 20% (w/v) solution was dialyzed against water using a
Slide-a-Lyzer dialysis cassette (molecular weight cutoff 3500) for
two days to remove salts. The ensuing concentration of aqueous silk
fibroin ranged from 5-7% (w/v), which was calculated by weighing
the remaining solid after drying. Silk solution was then
lyophilized. The lyophilized silk was next dissolved in
hexafluoroisopropanol (HFIP) to produce a 17% (w/v) silk
solution.
[0153] Preparation of Aqueous Silk-Glycerol Solutions
[0154] Silk fibroin solutions were prepared following published
procedures [1]. In brief, B. mori silk cocoons were boiled in 0.02M
aqueous Na.sub.2CO.sub.3 for 30 minutes to extract the sericin
component and isolate the silk fibroin protein. Isolated silk
fibroin was then washed three times for 20 minutes in deionized
water and allowed to dry for 48 hours at room temperature. Dried
silk was dissolved in 9.3M LiBr at 60.degree. C. for 4 h, and the
resulting 20% (w/v) solution was dialyzed against water using a
Slide-a-Lyzer dialysis cassette (molecular weight cutoff 3500) for
two days to remove salts. The ensuing concentration of aqueous silk
fibroin ranged from 5-7% (w/v), which was calculated by weighing
the remaining solid after drying. This solution was then
concentrated by exposing the cassette membrane to ambient air for
varying times to produce 10-20% (w/v) silk fibroin aqueous
solutions. Deionized water was blended with these silk solutions to
bring concentrations below 5%. All silk fibroin solutions were
stored at 4.degree. C. until use. Aqueous fibroin solution prepared
as described above was used to cast films. Films were fabricated as
previously described [2], blending aqueous fibroin with 99% (w/v)
glycerol to produce blends of 75:25 (dry weight) silk:glycerol
solution.
[0155] Controlled Nutrient Exchange
[0156] To improve controlled endothelialization and remodeling of
the anastomosis device, the wall formulation can modified to
incorporate finely tuned nano- or micro-porosities. Nano-porosity
in the wall of the vessel anastomosis device can facilitate
nutrient, oxygen, and waste exchange improving natural vessel
healing. The porosity can be tuned in such a way that a controlled
amount of fluid will be diffused to allow this beneficial exchange
without harmful loss blood pressure or volume. Two different
techniques were developed to incorporate micro- to nano-size
pores.
[0157] In the first technique, sodium chloride crystals (NaCl) were
suspended in HFIP silk solution (5% to 20%) with the final
concentration of NaCl ranging from <10 mg/ml to >250 mg/ml.
The silk/NaCl blend was coated onto Teflon rods of various
diameters and dried completely. The silk/NaCl tubes were then
stabilized in 100% methanol for 10 to 20 minutes to induce
beta-sheet crystallization of the silk. NaCl crystals were leached
out in deionized water.
[0158] In the second technique, poly(methyl methacrylate) (PMMA)
nano-spheres (of various controlled diameters) were blended with
aqueous silk solution. The nano-spheres were spun down and
re-suspended in an aqueous silk solution. The final concentration
of nano-spheres in silk solution was 1% or greater. To ensure a
porous luminal surface of the device, PMMA spheres suspended in
deionized water, were first coated on to the rod surface followed
by a coating of the silk/PMMA blend. Several layers of the blended
solution were then coated onto the Teflon rods as mentioned above
and dried. The silk/PMMA dried tubes were then immersed in Acetone
solution (100%-50%) to dissolve and leach out the PMMA spheres. The
porous silk tubes were then stabilized in 100% methanol for 10 to
20 minutes to induce beta-sheet crystallization of the silk and
then re-hydrated in deionized water.
Example 2
Analysis of Certain Exemplary Devices
[0159] Prototypes are mechanically evaluated for uniaxial
compressive and radial compressive strength. Three samples per
group were tested in simulated physiological conditions in PBS at
37.degree. C. Uniaxial compression testing was performed with a
uniaxial mechanical tester (model 3366, Instron Inc., Norwood,
Mass., US). The implants were positioned between two opposing
parallel plates. Compressive force was measured during compression
until the implant diameter was reduced to 70%. Radial strength was
assessed using a pressure chamber. Implants were fitted in latex
sleeves and external pressure was increased until collapse.
Collapse pressure was measured in pounds per inch.sup.2.
[0160] Anastomosis seal was evaluated using a peristaltic pump.
Porcine carotid arteries were excised and mounted inline of a
pump-driven aqueous flow loop using barb fittings, and secured
circumferentially with silk sutures. The arteries were transected
and anastomosed using each design for comparison. Flow was
increased by 100 mLmin.sup.-1 each hour until reaching 1600
mLmin.sup.-1, which is 7 times greater than physiological flow and
velocity.
[0161] Targeted vessel diameters are clinically evaluated prior to
implantation. With this information, anastomosis devices can sized
appropriately. Flow studies have found seals perform optimally when
the device internal diameter (I.D.) is equal to the loaded I.D. of
the blood vessel, and the blood vessel wall is displaced an
additional 11.5% by the implant wall. For example, if the vessel
I.D. is 2.6 mm, then an appropriately sized device would have an
I.D. of 2.6 mm but an outer diameter (O.D.) of 2.9 mm. However,
mechanical evaluation has shown the walls of these devices to
produce superior strength when at a thickness of 250 to 300 .mu.m.
Do to this reason; optimal sizing was reconsidered to incorporate
thicker implant walls. After reevaluation, optimal fitting in the
blood vessel from the previous example exhibiting a loaded I.D. of
2.6 mm, would now call for a device I.D. of 2.5 mm but an outer
diameter (O.D.) of 3 mm, producing an additional 15.5% dilation
rather than 11.5%. Preliminary surgical implantations have revealed
that certain embodiments, particularly those that use spherical
tips as part of the anastomosis mechanism, require reconsideration
of the implant dimensions to facilitate the procedure. In certain
embodiments where the spherical tip over-dilates the target vessel
in the range of 15%, the internal diameter of the implant should be
equivalent to 80% of the sphere outer diameter. This facilitates
implantation, sealing, and securing of the anastomosis. Preliminary
in vitro flow testing of certain anastomosis device designs (e.g.
as in FIGS. 3-4 and 6-7), has suggested compression of the
load-dilated vessel wall to 90% results in a secure seal.
[0162] The silk:glycerol implant material facilities superior drug
elution due to broad drug compatibility and aqueous processing
which is not possible with other competitive polymer designs that
require the use of harsh and toxic solvents. Our fabrication
techniques allow for discrete laminar drug loading within the
device body as well as surface treatments. This facilitates
programmable elution during degradation. Our material is also
compatible with most surface functionalization treatments.
Example 3
An Exemplary Sutureless Silk Anastomosis Device: Fabrication
Mechanics, and In Vivo Testing
[0163] The present Example describes certain sutureless silk
anastomosis devices designed to reduce surgical time and
difficulty, which may lead to less invasive cardiovascular
anastomosis. The implant utilizes a barb-and-seat compression
fitting composed of one male and two female components. The implant
body is resorbable and capable of eluting heparin. Custom
controlled extrusion equipment was designed in order to fabricate
the implants. The devices were evaluated using crush resistance,
retention strength, and leak resistance. Radial crush resistance is
in the range of metal vascular implants (3-4 psi). Insertion force
and retention strength of the anastomosis was dependent on fit
sizing of the male and female components and subsequent vessel wall
compression. Anastomotic burst strength was dependent on the amount
of vessel wall compression, and capable of maintaining higher than
physiological pressures. In initial screening using a porcine
implant, the devices functioned for 28 days (the length of study)
and histological sections revealed cellular infiltration within the
laminar structure of the male component, as well as at the
interface between the male and female components. Degradation and
absorption of the implant wall were observed. The speed per
anastomosis using this new device was much faster than current
systems, providing significant clinical improvement.
[0164] Introduction
[0165] As described herein, manual suturing is the current gold
standard for generating vascular anastomoses..sup.[1-4]
Reconstitution of blood supply via vessel anastomosis remains a
technically challenging and time consuming procedure with a steep
learning curve for surgeons. Suturing errors such as uneven
spacing, inversion of suture walls, and misalignment of the vessel
intima can lead to anastomotic leaks, thrombosis, prolonged
hospital stays and death..sup.[5-10] These and other factors have
contributed to the persistent failure rates in 2-6% of cases,
potential loss of reconstruction, and elevated health care
costs..sup.[11,12] There is increasing demand for an easy, time
saving, less damaging but reliable procedure to form vascular
anastomoses. This is particularly crucial in trauma, cardiac
surgery, and organ transplant surgery where patient survival is
dependent on clamp time or warm ischemia time.
[0166] The present invention encompasses the recognition that, by
decreasing the level of technical dexterity required for
anastomosis, pathways to less invasive tool and robotic facilitated
anastomosis may become available. Furthermore, development of
anastomosis devices which do not require highly skilled hands or
lengthy surgical times will allow the possibility of temporary
peripheral vessel bypass by minimally trained respondents in times
of emergency such as direct combat casualty care.
[0167] A variety of vascular anastomosis mechanisms and devices
have been pursued..sup.[13] Each anastomosis mechanism imparts
varying levels of security and implantation difficulty. The average
reported anastomosis time for these devices ranges from 14 to 100
minutes and requires use of specialized tools and a high level of
dexterity. Devices such as microclips,.sup.[14-16] ring
staplers,.sup.[17-19] and magnets.sup.[20-22] have been used to
improve sutureless anastomosis but due in part to the use of
non-degradable materials have been found to induce chronic trauma
to blood vessels after healing is complete..sup.[4,14,16-20,23-30]
The permanent nature of these implants raises increasing concerns
for growing children or adolescents suffering from congenital
disease or traumatic vascular injury..sup.[31,32] Current
experimental bioresorbable devices exhibit relatively weak
anastomotic pull out strength compared to permanent
alternatives..sup.[26]
[0168] The present Example describes a fully resorbable,
drug-eluting, sutureless anastomosis device for small to large
diameter vessels, which can decrease complexity and ischemic time
in vascular reconstructive surgical procedures. This device is
formed from silk protein and can handle high pressures (2.800 mmHg)
and flow rates, and facilitates extremely quick anastomosis
procedures (.about.1 minute) with minimum dexterity. The device
simplifies vascular anastomosis by providing a quick and feasible
mechanical union without the need for specialized proprietary
tools, piercing of vessel tissue, or tying of knots. The components
fit concentrically within and around the vessel, which allows the
device to align and complete the anastomosis procedure with single
sliding motion.
[0169] Results and Discussion
[0170] Device Fabrication and Anastomosis Strategy
[0171] Silk fibroin was used as the structural material to generate
the anastomosis devices, due to its strength and degradability. The
silk material can also be autoclaved for sterilization without loss
of mechanical integrity..sup.[33] Glycerol was used in the material
and is a simple metabolizable nontoxic sugar alcohol ubiquitous in
food and pharmaceutical industries. When blended, glycerol
stabilizes an intermediate conformation of crystallized silk which
produces a more flexible yet stable and strong film..sup.[34]
[0172] A micro-stepped extrusion system was developed to precisely
deposit layers of silk glycerol around Teflon-coated stainless
steel rods to fabricate the tubular film components (FIG. 12). The
silk deposition technique was optimized to provide consistent
outcomes and control over the fabrication process.
[0173] The device was designed based on targeted blood vessel
diameters, vessel wall thickness, and swelling ratio of the
hydrated device. The anastomosis strategy used three resorbable
components; two identical tubular clip sheaths with two opposing
holes and the third component is a tubular coupler terminating with
ellipsoid barbs at each end. The holes in the clip act as a
recessed seat for receiving the barbs of the coupler which
subsequently forms the anastomotic mechanical union (FIG. 13). The
anastomosed vessels were secured between the coupler and the two
clips and upon restoration of blood flow, blood passed from the
proximal vessel segment through the lumen of the silk implant and
then into the distal vessel segment (FIG. 13b). Couplers with an
outer diameter of 3 mm (approximately 300 .mu.m wall thickness)
were used for in vitro studies to match the luminal diameter of
porcine femoral vessels.
[0174] The implant body produced from silk was stiff in the dry
state yet progressively softened when hydrated. This property eases
implantation and then allows the implant to exhibit softer
properties after implantation, avoiding stress shielding and
minimizing the risk of long-term chronic irritation. Unlike
tyrosine-derived polycarbonate, salicylate, and magnesium alloys,
hydration of this silk material swells slightly after hydration in
physiological conditions (FIG. 14)..sup.[35] The outer diameter and
sidewall thickness of the coupler increased approximately 12% and
30%, respectively, after hydration. This property improved vessel
fit and more secure, in contrast to the shrinking observed with
polylactic acid implants..sup.[36] The design of this device was
limited by the degree of flow resistance due to the thickness of
the implant walls. The resistance to fluid flow and pressure change
across the implant as a function of wall thickness was estimated by
Poiseuille using the equations: R=8L.eta./.pi.r.sup.4 and
.DELTA.P=Q8L.eta./.pi.r.sup.4, respectively where R=resistance,
L=implant length, .eta.=viscosity, r=the implant luminal radius,
.DELTA.P=pressure change and Q=the volumetric flow rate. The
resistance and pressure change are inversely proportional to the
luminal radius raised to the fourth power, thus a small change in
radius has a significant impact. Although the implants are not
likely to experience pressures in the peak aortic range of 140 mmHg
or 19 kPa, we estimated the affect that this pressure would have on
radial displacement using tensile mechanical analysis of the
implant material. A stress of 25.6.+-.0.7 kPa resulted in a
2e.sup.-3.+-.7e.sup.-5% uniaxial strain, or radial displacement of
3.2e.sup.-4% considering .DELTA.r=.DELTA.x/2.pi., where .DELTA.x is
the change in strain. These small radial displacements are not
large enough to invalidate the estimations produced using
Poiseuille's equation for our purpose. The luminal diameter of the
anastomosis device did not deform significantly under physiological
pressures, thus we estimated that pressure drop due to the implant
was mainly a result of the reduction in luminal cross-sectional
area by the sidewalls of the device (Table 1).
TABLE-US-00001 TABLE 1 Flow resistance and subsequent pressure drop
caused by reduction of the cross-sectional area of the vessel
lumen, by the implant walls. Implant Wall Thickess [.mu.m] Vessel
Blood 0 100 175 250 300 400 500 Lumen Flow Pressure Drop [mm]
[ml/min] [mmHg] 1 200 35.7 87.1 200 571 1,393 22,287 NA 1.5 200
7.04 12.5 20.4 35.7 54.4 149 571 2 200 2.23 3.4 4.81 7.04 9.28 17.2
35.7 2.5 200 0.91 1.27 1.67 2.23 2.74 4.27 7.04 3 50 0.11 0.15 0.18
0.23 0.27 0.38 0.56 3 200 0.44 0.58 0.72 0.91 1.07 1.52 2.23 3 350
0.77 1.02 1.27 1.6 1.88 2.66 3.9 3.5 50 0.06 0.08 0.09 0.11 0.13
0.17 0.23 3.5 200 0.24 0.3 0.36 0.44 0.5 0.67 0.91 3.5 350 0.42
0.53 0.63 0.77 0.88 1.17 1.6 4 50 0.03 0.04 0.05 0.06 0.07 0.09
0.11 4 200 0.14 0.17 0.2 0.24 0.27 0.34 0.44 4 350 0.24 0.3 0.35
0.42 0.47 0.6 0.77 4.5 200 0.09 0.1 0.12 0.14 0.15 0.19 0.24 5 200
0.06 0.07 0.08 0.09 0.1 0.11 0.14 Blood Viscosity of 0.0035 (Pa s)
Implant length of 1 cm Systolic Flow of 50 ml/min Ave Flow of 200
ml/min Peak Diastolic Flow of 350 ml/min
[0175] An implant wall thickness of 300 .mu.m produced the maximum
radial strength per millimeter of mercury unit pressure drop within
the 4 mm vessel model, targeted for in vivo implantation, and
produced similar results for smaller caliber vessels. Additionally,
the implant wall thickness of 300 .mu.m produced the highest radial
strength to flow resistance ratio when estimated for average and
peak physiological flows within the vessel model. These results
supported the design of a 300 .mu.m implant wall thickness for use
in the porcine femoral vein.
[0176] Minimizing Technical Difficulty of Anastomosis
[0177] Anastomosis Procedure Time
[0178] A three-piece design facilitated faster anastomosis times
compared to other reported strategies (Table 2). Average reported
time to complete double-sided anastomosis via manual suturing was
reported in the range of 17 to 55 minutes..sup.[4,17,37] As an
alternative to sutures, device manufacturers such as Medtronic and
LeMaire, Inc. have developed nitinol (U-clip).sup.[14-16] and
titanium (AnastoClip VCS/GC).sup.[28-30] clips which are crimped to
anchor vessel ends circumferentially in an interrupted pattern. The
average reported time to complete anastomosis for both ends of a
vascular graft ranges from 14 to 18 minutes..sup.[14-16,28-30] In
contrast to anastomosis clips, manufacturers such as Vascular
Therapies and Synovis have developed stapling cartridges (One-shot
Vascular Therapies).sup.[25] and ring pin staples
(Synovis).sup.[17-19] which use a minimal number of components.
These devices complete anastomosis with a single crimping motion
but require an intricate loading process which extend the average
procedure from 14 to 30 minutes..sup.[17-19,25] The average double
sided anastomotic time using the new silk devices was approximately
1 minute.
TABLE-US-00002 TABLE 2 Comparison of available anastomosis
strategies. Device Anastomosis Mechanism Time .sup.a) Materials Ref
Handmade Standard interrupted 17-55 Nylon, .sup.[4,17,37] Sutures
or non-interrupted vessel Polyester, piercing technique with knots.
Silk, Catgut, etc. Medtronic Inserted through vessels similar 18
Nitinol .sup.[14-16] U-clip to sutures trailing a needle. Needle
guide is removed, and then each U-clip curls to simulate knots.
Vascular Unique stapling cartridge 30 Stainless .sup.[25] Therapies
utilizing six square steel One-shot points. Vessels are loaded and
anastomosis is completed using a specialized tool. LeMaire Inc.
Interrupted, vessel wall 14 Titanium .sup.[28-30] AnastoClip
penetrating or non- VCS/GC penetrating version clips applied with a
specialized tool. Synovis Blood vessel or graft ends 14 HIDP-E
.sup.b) .sup.[17-19] Ring Pin are pulled through then Stainless
Stapler everted onto the pins of Steel the coupler rings. The
Titanium rings are then compressed with a specialized stapling
instrument. Magnamosis Magnetic rings provide 100 NdFeB .sup.c)
.sup.[20-22] Magnetic non-piercing compression Teflon Rings
anastomosis. Rings can be delivered endoluminally. Baxter Adhesive
assists in 25 Fibrin .sup.[23] Healthcare anastomosis sealing, and
Glue Tissucol reduces time by reducing Nylon the number of sutures
Sutures and knots. Spiked Stent-graft outer surface 20 Stainless
.sup.[4] stent- contains metal spikes Steel graft which, when
dilated, penetrate Teflon the vessel walls to anchor the implant.
Hooked Proximal vessel end must be 11 PL-GC .sup.d) .sup.[26]
device completely inverted then wrapped around implant and secured
on sharp hooks. Distal vessel is next pulled over and secured on
hooks. Silk Coupler Non-piercing 3-piece 1 Silk and Clip
compression fitting Fibroin .sup.a) Reported anastomosis time,
rounded in minutes, required to anastomose both ends of a vascular
graft using this system .sup.b) High-density polyethylene .sup.c)
Neodymium-iron-boron .sup.d)
Poly(lactide-co-glycolide-co-caprolactone)
[0179] Simplified Mechanism and Assembly Feedback
[0180] The quick procedure provided by the present device was due
to the implementation of novel anastomotic strategies made
available through the use of silk. The slide and seat assembly
design which allowed the components to concentrically self-align
and complete the formation of the concentric seal was dependent on
the flexibility and radial strength of the polymer body.
Additionally, the assembly provided tactile confirmation of
anastomosis in the form of a steep decrease followed by increased
insertion resistance, as the coupler barb was positioned into the
clip recesses and became fully seated. These qualities reduced
technical dexterity requirements during device implantation.
[0181] Device Mechanical Properties
[0182] Radial Strength
[0183] The functional design of the device compression fitting
requires radial strength capable of maintaining radial tension at
the coupler bead and clip seat interface. Radial crush resistance
of the implant within a latex pressure chamber was dependent on
wall thickness (FIG. 15d). The maximum crush resistance of 4.48 psi
was obtained from the couplers of approximately 300 .mu.m wall
thickness, which was nearly 45% higher than self-expanding metallic
vascular implants. Further increases in the wall thickness
marginally increased the crush pressure but would significantly
increase flow resistance.
[0184] Assembly Force and Retention Strength
[0185] For assembly, the coupler outer diameter was matched to that
of each blood vessel lumen, but mated with tubular clips of various
internal diameters to achieve various compression strengths. The
insertion force and retention strength were dependent on fit sizing
of the male and female components and subsequent vessel wall
compression (FIG. 15). The fitment pairing mechanically
demonstrated the function of the directional barb-and-seat geometry
of the implant assembly which was designed to require more force to
disassemble compared to initial assembly force. The 90% compressed
vessel wall required the highest insertion force and may severely
damage the vessel. The 50% vessel compression yielded similar
pull-out force compared to 75% compression, however, the insertion
force for the later was significantly higher. A full table of
insertion force and retention strength per fitment is provided in
Table 3.
TABLE-US-00003 TABLE 3 Effect of vessel wall compression on
insertion force and pull-out retention strength. Wall Insertion
Retention Compression [%] Force [N].sup.a) Strength [N] 25 0.36
.+-. 0.21 0.48 .+-. 0.10 50 1.2 .+-. 0.06 4.4 .+-. 0.49 75 3.9 .+-.
0.85 4.7 .+-. 0.76 90 3.3 .+-. 0.48 11.6 .+-. 1.9
[0186] Peak Pressure Leak Resistance
[0187] The stability of the anastomotic seal was also dependent on
the percent compression of the vessel wall (FIG. 16). The luminal
cross-sectional area of the coupler was not changed in order to
preserve consistent flow resistance (FIG. 17). At the lower vessel
compression (approximately 25%) the failure occurred due to
slippage of the coupler past the seat, while at 50% compression and
above the mechanism of failure was tearing of the seat of the
external clip. Although all compression settings failed at
pressures greater than average physiologically relevant pressure,
the 25% compression fitting demonstrated the potential to fail at
reported peak physiological pressures..sup.[38,39] A minimum wall
compression greater than 25%, such as 50%, would be often
recommended to confidently support peak pressures as well as resist
failure due to longitudinal strains physiologically relevant to a
mobile animal.
[0188] Anti-Thrombotic Drug Elution
[0189] The erosion of the device progresses from the luminal
surface due to direct contact with fluid flow (water or blood). In
accordance with the present invention, deposition of multiple
layers of silk could be used to entrap various drugs (antiplatelet,
antiproliferative) in each layer of the coupler sidewall which
would elute as the couplers erode in vivo. This feature is
characteristic of certain silk vascular tubes. The present
invention encompasses the recognition that this approach presents a
unique opportunity to locally deliver multiple drugs over several
time scales to treat a variety of clinical conditions. Furthermore,
the present invention encompasses the recognition that the ambient
processing conditions of silk facilitate the incorporation of
sensitive drugs. This feature provides a clear advantage to using
resorbable polymer-based devices over metal-based implants.
[0190] In the present study, we coated the luminal surfaces with
heparinized-silk or hydrated the devices with heparinized solution
and performed the release kinetics of the same drug for up to 24
hours. The hydrated heparin-loaded devices rapidly released most of
the drug, while the dry luminally-coated couplers exhibited delayed
release (FIG. 18). This delay in release was likely due to the
absorption of the drug during the drying process of the lumen
coating. Once the coupler lumen had hydrated during the study the
release rate of the remaining drug was similar. By the 24 hour time
point, the luminally-coated devices released approximately 20% more
heparin than the devices loaded via hydration with heparin
solution.
[0191] Silk degrades into amino acids over the course of weeks to
years with no known bioburdlens..sup.[33,40] In contrast to other
common degradable polymers (collagens or polyesters such as PLGA),
silk has been reported to be less immunogenic and
inflammatory.sup.[41,42] and has been reported to be used
successfully as implants in small diameter blood vessels in a
number of animal studies.sup.[40,41,43] and as sutures for decades
(FDA approved).
[0192] Surface Texture and Storage Life
[0193] The resorbable nature of silk has an impact on surface
texture which may dictate implant shelf-life and storage
strategies. FIG. 16 shows interferograms of the luminal surface of
couplers stored in deionized water for up to six months. The
average roughness of the as-made device was approximately 10 nm and
after six months of storage, the surface roughness was still in
sub-micron ranges. Surface roughness can have a large effect on
platelet deposition but the roughness of the silk implant body was
negligible at the time of initial fabrication, and remained minimal
and within the range of current stents at the storage time point of
1 month..sup.[44,45]
[0194] Sutureless Resistance to Strains In Vivo
[0195] Anastomosis of Porcine Femoral Vein
[0196] Porcine animal models allowed a more accurate design and
analysis of implant geometries appropriate for humans, and thus
allowed insight into surgical strategies and to the hurdles of
human size implantation procedures. The femoral vessels, which span
from the knee to groin, are large vessels subjected to significant
mechanical strains in mobile animals. These strains are transferred
to the anastomosis device and can be a source of failure. The
anastomosis device was implanted into a porcine femoral vein and
evaluated for mechanical performance related to the sutureless
anastomotic seal in vivo for 4 weeks (FIG. 19). The coupler had a
wall thickness of 250 .mu.m and the outer diameters of the coupler
body and ellipsoid tips measured 3.5 mm and 4.75 mm, respectively,
when fully hydrated. The coupler was inserted into a 3.5 to 4.5 mm
femoral vein with approximately 600 .mu.m wall thickness. The clips
had an inner diameter of 5.15 mm which produced approximately 70.8%
compression of the vessel wall. The seat diameters were 3 mm.
[0197] Initial implantation of the coupler into the femoral vein
was impeded by vessel retraction after transection. The couplers
were designed to function with minimal axial length. Anastomoses of
the gap, which developed between vessel stumps, required a large
amount of axial strain to be applied to the device. However, our
design can be fabricated in various lengths to provide dual
function as a vascular graft between vessel segments.
[0198] Animal Behavior and Mobility
[0199] At day 1, 12 hours after surgical anastomosis of the femoral
vein, the incisions were intact with minimal swelling and did not
exhibit elevated temperatures. Before the 24 hour mark, the animal
was ambulatory and capable of weight bearing in both hind legs. The
animal could support himself up from seated position without assist
and could ambulate steadily, with ten minutes of walking as the
limit before sitting. Behavior was otherwise favorable and included
taking treats, matt chewing, and socializing with other pigs.
Ketofen, Buprenex, and a Fentanyl patch were administered to
control pain and subsequent limping. Gabapentin was used to address
the potential nerve irritation/inflammation. At day 3 medication
was reduced to one dose of Ketophen and limping was no longer
observed when the animal was ambulatory and behavior remained
favorable. Restored mobility did not compromise the incisions which
remained intact and appeared to be healing optimally. At day 10
after surgery there appeared to be seromas under the incisions at
the femoral implant sites. A hand-held Doppler ultrasound unit was
used to verify flow distal to the graft implant sites to confirm
the swellings were not hematomas due to catastrophic leakage from
the anastomosis. The swellings soon disappeared within hours
without any interventional treatment and all incisions were clear
of redness and continued healing.
[0200] The main goal was to demonstrate the mechanical integrity of
the resorbable sutureless compression anastomosis system. The
anastomosis device was implanted in vivo into a porcine femoral
vein, without long-term supplementation with antithrombotics or
antiproliferatives. The device successfully maintained anastomosis
of the vessel for the length of the 28 day study.
[0201] Histology
[0202] The influence of the device on vascular outcomes at the site
of anastomosis was assessed relevant to endothelialization and
smooth muscle hyperplasia. Upon excision, the device was found
completely covered with new tissue completing the anastomosis.
[0203] Histological sections revealed cellular infiltration within
the laminar structure of the male component, as well as at the
interface between the male and female components (FIG. 20).
Histological sections exhibited artifacts in the form of shrinking
of the implant walls and separation of neointimal tissue from the
implant. However, initial stages of degradation and absorption of
the implant wall were also observed. The degree of neointimal
tissue was consistent with what was seen for metal and
polymeric.sup.[46,47] vascular implants, such as stents.sup.[47-49]
and grafts,.sup.[50-52] implanted in the absence of long-term
antiproliferative or antithrombotic drug therapies or, in some
cases, with delivery of suboptimal
therapeutics..sup.[48,49,53,54]
[0204] Antiproliferatives, and standard drug therapies were
excluded from our initial study to generate an understanding of the
baseline occlusion in the absence of commonly administered
treatments. Preliminary observations of neointimal tissue
development in the absence of drug therapies will provide an
understanding necessary to formulating a drug therapy optimized
specifically to the device. Hematoxylin and Eosin (H & E)
staining of the occlusion developed within the device demonstrated
the organization and the presence of recanalization (FIG. 20a).
Factor VIII immunohistochemistry demonstrated that the
recanalization was lined with endothelial cells (FIG. 20b).
Collagen deposition was revealed using Trichrome staining (FIG.
20c). Cells within the occlusion and recanalization were positive
for smooth muscle actin suggesting the occlusion was a result of
smooth muscle hyperplasia (FIG. 20d). Future drug therapies
accompanying the device will likely include everolimus to target
hyperplasia in order to compare the present data.
[0205] Conclusions
[0206] The majority of vascular anastomotic failures are thought to
be due to technical errors as manual suturing demands a high degree
of technical skill and dexterity. The present Example describes a
mechanically sufficient yet quicker sutureless anastomosis
mechanism using resorbable materials capable of drug-elution. The
design and material addressed determined advancements and
limitations of competitive approaches. The silk material
facilitated fabrication without the need for toxic solvents and can
be fabricated in a variety of diameters and lengths to support
various anastomosis scenarios. The axial retention and burst
strength were evaluated, as was the resistance generated by the
implant geometry. Anastomoses formed using the device were secure,
and supported burst pressures and flow-rates one order of magnitude
beyond physiological peaks. The device successfully maintained
anastomosis of the femoral vein in vivo for the length of the 28
day study. The robust performance of the compression style seal
leaves opportunity for future design improvements favoring
flexibility and permeability of the device body. It will be
appreciated that provided technologies are applicable to neointimal
tissue growth. In some embodiments, provided technologies will
include administering antiproliferative and/or antithrombotic
therapies, for example according to industry standards.
[0207] The speed per anastomosis using the device was one of the
fasted reported, and a fraction of the time compared to modern
clinically available options. Much of the observed time savings can
be attributed to the minimalistic component system with an
intuitive self-aligning concentric design, the single
circumferentially lined seal, and the positive tactile confirmation
of completion. The device has the potential to decrease complexity
of procedures, and to minimize ischemia and surgical times, while
providing confidence in the anastomotic seal. The design may also
support strategies compatible with the use of less invasive
catheter or robotic mediated procedures.
[0208] Experimental Section
[0209] Materials
[0210] Cocoons of the silkworm Bombyx mori were supplied by Tajima
Shoji Co. (Yokohama, Japan). Sodium carbonate, lithium bromide, and
Glycerol MW 92.09, were purchased from Sigma-Aldrich Corp. (St.
Louis, Mo., US). Porcine femoral vessels from 6-9 month old 250 lb.
Yorkshire pigs were ordered from Animal Technologies, Inc. (Tyler,
Tex., US). Heparin and Fluorescein conjugated Heparin was purchased
from Invitrogen Life Technologies (Grand Island, N.Y., US).
[0211] Preparation of Aqueous Silk-Glycerol Solutions
[0212] Aqueous silk fibroin solutions were prepared following
published procedures..sup.[55] Aqueous fibroin solutions were
blended with 99% (w/v) glycerol, as previously described,.sup.[34]
to produce blends of 80:20 (dry weight) silk:glycerol solution.
[0213] Fabrication of Device Components
[0214] The anastomosis device design was composed of two parts as
described in FIG. 12. Part 1 was an intraluminal coupler, which was
a cylindrical tube with spherical barb tips at each end. The
tubular component of the coupler was fabricated by coating aqueous
silk:glycerol (20% dry wt. glycerol) solution on to the Teflon
coated stainless steel rods (0.65 to 6 mm diameter) using a
microstep controlled extruder and lathe (FIG. 12a). The coating was
allowed to dry and each coating produced a 40 .mu.m thick tubular
film layer (FIG. 14) and subsequent layers were deposited to
achieve the target (150 to 300 .mu.m) thickness. Lower
concentrations of silk:glycerol can be used to generate thinner
layers. The ellipsoid barb tips were produced in a separate step by
dispensing 5 to 50 .mu.l of silk:glycerol solution onto the
previously coated rods. The final outer diameter of the barbs were
equivalent to approximately 125% of the outer diameter of the
coated rods (FIG. 12b). Part 2 (FIG. 12f) was a tubular sheath clip
fabricated by same technique to achieve thickness of 250 .mu.m. Two
or more opposing holes were excised from the sheath using a biopsy
punch to form a recess seat. The holes were sized according the
dimensions of the ellipsoid tip to be received.
[0215] Surface Analysis
[0216] A scanning white-light interferometer (New View 600, Zygo
Co., Middlefield, Conn., US) was used to measure topography, and
profile. A 10.times. interferometric objective was used to scan the
film in the Z-axis 5 .mu.m below and above the surface plane to
produce a 3D interferogram. Roughness (R.sub.a) was measured along
a 500 .mu.m linear section on the luminal surface of 5 implants per
time point (1, 30, or 180 days storage in sterile DI H.sub.20).
R.sub.a was expressed as
R.sub.a=1/n.SIGMA..sub.i=1.sup.n|.gamma..sub.i| where .gamma..sub.i
is the difference in height between any measured point and the
calculated mean sample height.
[0217] Swelling of Components
[0218] Five devices with 6 mm outer diameter were subjected to
dehydration for seven days at ambient conditions, then rehydration
in deionized water for 24 hours. Changes in diameter and wall
thickness were measured using cylindrical class ZZ plug gauges
(model 102100200, Vermont gauge, Swanton, Vt., US) and an
electronic micrometer (model 293-831, Mitutoyo Corp., Aurora, Ill.,
US).
[0219] Mechanical Analysis
[0220] The coupler-vessel insertion force and anastomotic pull-out
force was measured using uniaxial mechanical tester (model 3366,
Instron Inc., Norwood, Mass., US). Insertion and pull-out tests
were performed in triplicate at room temperature and repeated using
four different assembly fitments which ranged in tightness.
Tightness was measured as the amount of vessel wall compression
produced between the outer diameter of the spherical bead tip of
the coupler, and the inner diameter of the clip lumen. The four
ranges were assembly fitments producing 25%, 50%, 75%, or 90%
compression of the blood vessel wall (FIG. 17). Forces were
measured in Newtons. In the insertion force test the anastomosis
clip over cadaver vessel segments was concentrically aligned over
the fixed coupler and the construct was compressed in between two
parallel plates in line with the load cell (FIG. 15). The construct
was compressed at a rate of 1 mm/min until the holes of tubular
sleeve received the spherical barbs of the coupler thereby
completing the assembly procedure (FIG. 15B). Pull-out force was
measured by pulling the proximal and distal anastomosed vessel
segments in opposing directions (FIG. 15C). Radial strength was
assessed using a pressure chamber. A coupler was placed within a
sealed latex sleeve. The external pressure was increased in steps
until coupler collapse. Collapse pressure was measured in pounds
per inch2.
[0221] Analysis of Anastomotic Seal
[0222] Anastomotic seal was evaluated using a peristaltic pump and
polyethylene terephthalate (PET) tubing. Anastomosis was performed
as mentioned above by securing couplers into the proximal and
distal ends of the vessel segment and free end of each coupler was
tightly fit into PET tubing to close the flow loop (FIG. 16a).
Phosphate buffered saline was flowed through the flow loop with an
increased in flow rate by 4 mLmin.sup.-1 each second until
anastomotic failure was reached. A butterfly valve placed inline
distal to the anastomosis to restrict the flow and to increase the
line pressure until anastomotic failure was reached. Experiments
were performed in triplicate.
[0223] Heparin Release Kinetics
[0224] Coupler devices were soaked in fluorescein conjugated
heparin solution (0.5 mg/ml in deionized water) using two different
techniques. Either the luminal surface of the couplers were coated
with fluorescein conjugated heparin solution or the coupler devices
were completely submerged into the solution for 24 hours (FIG.
18a). After equilibration for 24 hours, the couplers were rinsed
with deionized water and secured between two segments of silicon
tubing mounted in line with a standard perfusion system to mimic
dynamic flow conditions for drug release (FIG. 18b). The devices
were perfused at a rate of 2 ml/min for 1 hour and 1 ml/hr for 24
hours using deionized water. The perfused silk couplers were
removed from the perfusion system and then dissolved in lithium
bromide solution to quantify the remnant drug. The dissolved
samples and standards (known amount of fluorescein conjugated
heparin in silk/lithium bromide solution) were measured (at 495 nm
excitation and 515 nm emission) using a plate reader (Molecular
Device, LLC, model: SpectraMax M12, Sunnyvale, Calif.) and plotted
in micro-grams. The error bars represent the standard deviation and
n=5 per condition and time point.
[0225] In Vivo Implantation
[0226] Implantations were conducted according to the
recommendations of IACUC at an approved DLAM facility. The surgical
procedures were performed according to our IACUC approved protocol
(B2012-130 A-4). Surgeries were performed on a 30 kg male Yorkshire
pig. Telazol mixture (Telazol, 8 mg/kg+Ketamine, 4 mg/kg+Xylazine,
4 mg/kg) was administered as a pre-anesthetic. Sedation was
supplemented via Isoflurane gas mask at 3-4%. The vascular site was
prepped and draped in a sterile manner after an adequate anesthetic
plane is obtained. A 6-8 cm incision from the inguinal region down
the medial aspect of the hind leg was performed to access the
common femoral vein. The vascular bundle was identified as it
entered the quadriceps musculature. Proximal and distal control was
obtained with application of vascular clamps. The femoral vein was
transected and the lumens were then flushed with dilute heparinized
saline. Anastomosis was performed as described previously in FIG.
13 (see also FIG. 21). Upon removal of clamps (first distal then
proximal) and restoration of blood flow, blood passes from the
proximal vessel segment through the lumen of the silk implant then
into the distal vessel segment. No sutures were used to assist
anastomosis. The incision was then closed in layers with 4-0
Monocryl deep dermal and subcuticular sutures.
[0227] Implanted Device Retrieval
[0228] At the terminal time point of 4 weeks the pig had grown to
70 kg. The animal was anesthetized as mentioned above and a 6-8 cm
incision from the inguinal region down the medial aspect of the
hind leg was made to access and excise the region of the femoral
vein which contained the implanted anastomosis device. Both
proximal and distal control of the vein was obtained with
application of vascular clamps. We first transected the segment of
the vessel distal to the implant to observe for bleeding (i.e.
perfusion) and thus ensure patency. The distal segment was then
clamped. Next, the segment of the vessel proximal to the implant
was clamped and transected to enable removal the implant while
inducing temporary ischemia. The implant and vessel construct was
then be prepped for histological analysis and stored in formalin.
The wounds were left open. Euthasol IV (Pentobarbital 390
mg/Phenytoin 50 mg), at 0.22 mL/kg, was administered intravenously
immediately following these procedures.
[0229] Histological Staining
[0230] The retrieved segment of vessel and coupler was
cross-sectioned transversely such that each section consists of
concentric layers of: scar-implant-vein-implant-scar. The
vein/implant construct was bisected for embedding in paraffin.
After embedding was complete, the blocks were further sectioned
from the proximal to the distal end to produce six cross-section
slides every 2 mm. The sections received one of six treatments,
three of which were stained with H&E, trichrome, or Verhoeffs
Elastic Stain. The remaining three were treated for
immunohistochemistry (IHC). The IHC treatments were Factor VIII,
CD31, or Smooth Muscle Actin. [0231] [1] E. L Chang, M. G. Galvez,
J. P. Glotzbach, C. D. Hamou, S. El-ftesi, C. T. Rappleye, K.-M.
Sommer, J. Rajadas, O. J. Abilez, G. G. Fuller, M. T. Longaker, G.
C. Gutner, Nat. Med. 2011, 17, 1147. [0232] [2] J. G. Motwani, E.
J. Topol, Circulation 199, 97, 916. [0233] [3] S. M. Schwartz, D.
deBlois, E. R. M. O'Brien, Circ. Res. 1995, 77, 445. [0234] [4] S.
Abou Tasm, J.-F. Garbe, M. Boufi, J.-P. Bossavy, J.-B. Ricco, J.
Vasc. Surg. 2012, 55, 210. [0235] [5] A. E. Beris, M. G. Lykissas,
A. V Korompilias, G. I. Mitsionis, M. D. Vekris, I. P.
Kostas-Agnantis, Arch. Orthop. Trauma Surg. 201, 130, 1141. [0236]
[6] F. M. Ameli, J. L. Provan, C. Williamson, P. M. Keuchler, J.
Cardiovasc. Surg. (Torino), n.d., 28, 695. [0237] [7] M. Ojha, R.
L. Leask, K. W. Johnston, T. E. David, J. Butany, Ann. Thorac.
Surg. 2000, 70, 1338. [0238] [8] M. D. Mary E. Charlson, M. D. O.
Wayne Isom, N. Engl. J. Med. 2003, 348, 1456. [0239] [9] B. N.
French, N. B. Rewcastle, Stroke 1977, 8, 597. [0240] [10] T.
Zubilewicz, J. Wronski, A. Bouriez, P. Terlecki, A. M. Guinault, B.
Muscatelli-Groux, J. Michalak, D. Melliere, J. P. Becquemin, E.
Allaire, Med. Sci. Monit. 2001, 7, 316. [0241] [11] J. J. Disa, P.
G. Cordeiro, D. A. Hidalgo, Plast. Reconstr. Surg. 1999, 104, 97.
[0242] [12] D. T. Bui, P. G. Cordeiro, Q.-Y. Hu, J. J. Disa, A.
Pusic, B. J. Mehrara, Plast. Reconstr. Surg. 2007, 119, 2092.
[0243] [13] G. Pratt, W. Rozen, A. Westwood, A. Hancock, D. Chubb,
M. W. Ashton, I. S. Whitaker, Microsurgery 2012, 32, 68. [0244]
[14] R. C. Baynosa, R. Stutman, R. C. Mahabir, W. A. Zamboni, K. T.
Khiabani, J. Reconstr. Microsurg. 2008, 1, 39. [0245] [15] J.
Taylor, R. Katz, N. Singh, Microsurgery 2006, 26, 550. [0246] [16]
A. K. Bigdeli, I. Kaczmnaek, S. Eifett, A. Beirs-Fernandez, S.
Kober, K. Nikolaou, M. Oberhoffer, C. Vicol, Eur. J. Cardiothorac.
Surg. 2011, 40, e93. [0247] [17] W. M. Rozen, I. S. Whitaker, R.
Acosta, Anticancer Res. 2010, 30, 1293. [0248] [18] I. Ducic, B. J.
Brown, S. S. Rao, Microsurgery 2011, 31, 360. [0249] [19] G. Ye,
H.-G. Mo, Z.-H. Wang, S.-H. Yi, X.-W. Wang, Y.-F. Zhang, J. Urol.
2006, 175, 636. [0250] [20] D. Erdmann, R. Sweis, C. Heitmann, K.
Yasui, K. C. Olbrich, L. S. Levin, a A. Sharkawy, B. Klitzman, J.
Vasc. Surg. 2064, 40, 505. [0251] [21] R. Jamshidi, J. T.
Stephenson, J. G. Clay, K. O. Pichakron, M. R. Harrison, J.
Pediatr. Surg. 2009, 44, 222. [0252] [22] J. Wall, M. Diana, J.
Leroy, V. Derujiter, K. D. Gonzales, V. Lindner, M. Harrison, J.
Marescaux, Endoscopy 2013, 45, 643. [0253] [23] A. B. Cho, T. H.
Wei, L. R. Torres, R. M. J nior, G. M. Rugiero, M. A. Aita,
Microsurgery 2669, 29, 24. [0254] [24] L. Wiklund, L. F. Bonilla,
E. Berglin, J. Thorac. Cardiovasc. Surg. 2005, 129, 146. [0255]
[25] L. Liu, J. Liu, M. Zhu, S. Hu, Ann. Thorac. Surg. 2006, 82,
303. [0256] [26] K. Ueda, T. Mukai, S. Ichinose, Y. Koyama, K.
Takakuda, Microsurgery 2010, 30, 494. [0257] [27] M. Taylor, L.
Bumanlag, . . . Am. Leather . . . 2009, 104, 79. [0258] [28] C. J.
Zeebregts, W. M. Kirsch, J. J. van den Dungen, Y. H. Zhu, R. van
Schilfgaarde, Am. J. Surg. 2064, 187, 751. [0259] [29] C. J.
Zeebregts, Br. J. Surg. 2005, 92, 654. [0260] [30] P. Aarnio, O.
Jarvinen, P. Varjo, Int. J. Angiol. 2000, 9, 62. [0261] [31] B. H.
Goldstein, R. Hirsch, M. E. Zussman, J. a Vincent, A. J. Torres, J.
Coulson, R. E. Ringel, R. H. Beekman, Am. J. Cardiol. 2012, DOI
10.1016/j.amjcard.2012.06.063. [0262] [32] I. Gonzalez, D. Kenny,
S. Slyder, Z. M. Hijazi, Pediatr. Cardiol. 2012, DOI
10.1007/s00246-012-0439-9. [33]G. H. Altman, F. Diaz, C. Jakuba, T.
Calabro, R. L. Horan, J. Chen, H. Lu, J. Richmond, D. L. Kaplan,
Biomalerials 2003, 24, 401. [0263] [34] S. Lu, X. Wang, Q. Lu, X.
Zhang, J. a Kluge, N. Uppal, F. Omeneto, D. L. Kaplan,
Biomacromolecules 2010, 11, 143. [0264] [35] B. D. Lawrence, S.
Wharram, J. a Kluge, G. G. Leisk, F. G. Omenetto, M. I. Rosenblatt,
D. L. Kaplan, Macromol. Biosci. 2010, 10, 393. [0265] [36] J. a
Ormiston, P. W. S. Serruys, Circ. Cardiovasc. Interv. 2009, 2, 255.
[0266] [37] M. S. Alghoul, C. R. Gordon, R. Yetman, G. M. Buncke,
M. Siemionow, A. M. Afifi, W. K. Moon, Microsurgery 2011, 31, 72.
[0267] [38]C. Stick, U. Hiedl, E. Witzleb, Eur. J. Appl. Physiol.
Occup. Physiol. 1993, 66, 434. [0268] [39] H. P. von Schroeder, R.
D. Coutts, E. Billings, M. T. Mai, M. Aratow, Clin. Orthop. Relat.
Res. 1991, 218. [0269] [40] X. Wang, X. Zhang, J. Castellot, I.
Herman, M. Iafrati, D. L. Kaplan, Biomaterials 2008, 29, 894.
[0270] [41] B. Panilaitis, G. H. Altman, J. Chen, H.-J. Jin, V.
Karageorgiou, D. L. Kaplan, Biomaterials 2003, 24, 3079. [0271]
[42] L. Meinel, S. Hofmann, V. Karageorgiou, C. Kirker-Head, J.
McCool, G. Gronowicz, L. Zichner, R. Langer, G. Vunjak-Novakovic,
D. L. Kaplan, Biomaterials 2005, 26, 147. [0272] [43] F. Huang, L.
Sun, J. Zheng, Artif. Organs 2008, 32, 932. [0273] [44] J.
Linneweber, P. M. Dohmen, U. Kertzscher, U. Kerzscher, K. Affeld,
Y. Nose, W. Konertz, Artif. Organs 2007, 31, 345. [0274] [45] A.
Dibra, A. Kastrati, J. Mehilli, J. Pache, R. von Oepen, J.
Dirschinger, A. Schomig, Catheter. Cardoivasc. Interv. Off. J. Soc.
Card. Angiogr. Interv. 2005, 65, 374. [0275] [46] W. J. van der
Giessen, a M. Lincoff, R. S. Schwartz, H. M. van Beusekom, P. W.
Serruys, D. R. Holmes, S. G. Ellis, E. J. Topol, Circulation 1996,
94, 1690. [0276] [47] C. Macaya, Vasc. Health Risk Manag. 2012, 8,
125. [0277] [48] M. Hamilos, J. Sarma, M. Ostojic, T. Cuisset, G.
Sarno, N. Melikian, A. Ntalianis, O. Muller, E. Barbato, B.
Beleslin, D. Sagic, B. De Bruyne, J. Bartunek, W. Wijns, Circ.
Cardiovasc. Interv. 2008, 1, 193. [0278] [49] T. Palmerini, G.
Biondi-Zoccai, D. Della Riva, C. Stettler, D. Sangiorgi, F.
D'Ascenzo, T. Kimura, C. Briguori, M. Sabate, H.-S. Kim, A. De
Waha, E. Kedhi, P. C. Smits, C. Kaiser, G. Sardella, A. Marullo, A.
J. Kirtane, M. B. Leon, G. W. Stone, Lancet 2012, 379, 1393. [0279]
[50] V. Mickley, Nephrol. Dial. Transplant. 2004, 19, 309. [0280]
[51] V. Farooq, P. W. Serruys, Y. Zhang, M. Mack, E. Stahle, D.
Rholmes, T. Feldman, M.-C. Morice, A. Colombo, C. V Bourantas, T.
de Vries, M.-A. Morel, K. Ddawkins. A. Kappetein, F. W. Mohr, J.
Am. Coll. Cardiol. 2013, DOI 10.1016/j.jacc.2013.07.106. [0281]
[52] N. Vasi , L. Davidovic, D. Markovi , M. Sladojevi , Vojosanit.
Pregl. 2013, 70, 740. [0282] [53] M. M. Wong, B. Winkler, E.
Karamariti, X. Wang, B. Yu, R. Simpson, T. Chen, A. Margariti, Q.
Xu, Arterioscler. Thromb. Vasc. Biol. 2013, 33, 2397. [0283] [54]
T. Tada, K. Kadota, S. Kubo, M. Ozaki, M. Yoshino, K. Miyake, H.
Eguchi, N. Ohashi, Y. Hayakawa, N. Saito, S. Otsuru, D. Hasegawa,
Y. Shigemoto, S. Habera, H. Tanaka, Y. Fuku, N. Oka, H. Kato, H.
Yamamoto, T. Goto, K. Mitsudo, Circulation 2011, 124: A1491. [0284]
[55] M. L. Lovett, C. Cannizaro, L. Daheron, B. Messmer,
Biomaterials 2007, 28, 5271.
REFERENCES
[0284] [0285] 1. Lovett M L, Cannizzaro C, Daheron L. Messmer B.
Silk fibroin microtubes for blood vessel engineering. Biomaterials.
2007; 28(35):5271-9. [0286] 2. Lu S, Wang X, Lu Q, Zhang X, Kluge J
a, Uppal N, et al. Insoluble and flexible silk films containing
glycerol. Biomacromolecules. 2010 Jan. 11; 11(1):143-50. [0287] 3.
Zhang X, Wang X, Keshav V, Wang X, Johanas J T, Leisk G G, t al.
Dynamic culture conditions to generate silk-based tissue-engineered
vascular grafts. Biomaterials. 2009 July; 30(19):3213-23. [0288] 4.
Chang El, Galvez M G, Glotzbach J P, Hamou C D, El-ftesi S,
Rappleye C T, et al. Vascular anastomosis using controlled phase
transitions in poloxamer gels. Nature medicine. 2011 September;
17(9): 1147-52. [0289] 5. Motwani J G, Topol E J. Aortocoronary
saphenous vein graft disease: pathogenesis, predisposition, and
prevention. Circulation. 1998 Mar. 10; 97(9):916-31. [0290] 6.
Schwartz S M, deBlois D, O'Brien E R M. The Intima: Soil for
Atherosclerosis and Restenosis. Circulation Research. 1995 Sep. 1;
77(3):445-65. [0291] 7. Abou Taum S, Garbe J-F, Boufi M, Bossavy
J-P, Ricco J-B. Experimental study of a novel mechanical connector
for sutureless open arterial anastomosis. Journal of vascular
surgery. 2012 January; 55(1):210-5. [0292] 8. Disa J J, Cordeiro P
G, Hidalgo D A. Efficacy of conventional monitoring techniques in
free tissue transfer: an 11-year experience in 750 consecutive
cases. Plastic and reconstructive surgery. 1999 July;
104(1):97-101. [0293] 9. Bui D T, Cordeiro P G, Hu Q-Y, Disa J J,
Pusic A. Mehrara B J. Free flap reexplortion: indications,
treatment, and outcomes in 1193 free flaps. Plastic and
reconstructive surgery. 2007 June; 119(7):2092-100. [0294] 10.
Beris A E, Lykissas M G, Korompilias A V, Mitsionis G I, Vekris M
D, Kostas-Agantis I P. Digit and hand replantation. Archives of
orthopaedic and trauma surgery. 2010 September; 130(9):1141-7.
[0295] 11. Ameli F M, Provan J L, Williamson C, Keuchler P M.
Etiology and management of aorto-femoral bypass graft failure. The
Journal of cardiovascular surgery. 28(6):695-700. [0296] 12. Ojha
M. Leask R L, Johnston K W. David T E, Butany J. Histology and
morphology of 59 internal thoracic artery grafts and their distal
anastomoses. The Annals of thoracic surgery. 2000 October;
70(4):1338-44. [0297] 13. Mary E. Charlson M D. O. Wayne Isom M D.
Care after Coronary-Artery Bypass Surgery. The New England Journal
of Medicine. 2003; 348:1456-63. [0298] 14. French B N. Rewcastle N
B. Recurrent stenosis at site of carotid endarterectomy. Stroke.
1977; 8(5):597-605. [0299] 15. Zubilewiez T, Wronski J, Bourriez A,
Terlecki P, Guinault A M, Muscatelli-Groux B, et al. Injury in
vascular surgery--the intimal hyperplastic response. Medical
science monitor. 2001; 7(2):316-24. [0300] 16. Pratt G, Rozen W,
Westwood A, Hancock A, Chubb D, Ashton M W. et al.
Technology-assisted and suturless microvascular anastomoses:
Evidence for current techniques. Microsurgery. 2012; 32(1):68-76.
[0301] 17. Cho A B, Wei T H, Torres L R, Junior R M, Rugiero G M,
Aita M A. Fibrin glue application in microvascular anastomosis:
comparative study of two free flaps series. Microsurgery. 2009
January; 29(1):24-8. [0302] 18. Erdmann D, Sweis R, Heitmmmann C,
Ysui K, Olbrich K C, Levin L S, at al. Side-to-side sutureless
vascular anastomosis with magnets. Journal of vascular surgery.
2004 September; 40(3):505-11. [0303] 19. Wiklund L, Bonills L F,
Berglin E. A new mechanical connector for distal coronary artery
anastomoses in coronary artery bypass grafting: a randomized,
controlled study. The Journal of thoracic and cardiovascular
surgery. 2005 January; 129(1):146-50. [0304] 20. Liu L, Liu J, Zhu
M, Hu S. Experimental study of one-shot vascular anastomostic
device for proximal vein graft anastomoses. The Annals of thoracic
surgery. 2006 July; 82(1):303-6. [0305] 21. Ueda K, Mukai T,
Ichinose S, Koyama Y, Takakuda K, Bioabsorbable device for
small-caliber vessel anastomosis. Microsurgery. 2010 September;
30(6):494-501. [0306] 22. Alghoul M S, Gordon C R, Yetman R, Buncke
G M, Siemionow M, Afifi A M, et al. From simple interrupted to
complex spiral: a systematic review of various suture techniques
for microvascular anastomoses. Microsurgery. 2011 January;
31(1):72-80. [0307] 23. Ormiston J a, Serruys P W S. Bioabsorbable
coronary stents. Circulation. Cardiovascular interventions. 2009
June; 2(3):255-60. [0308] 24. Erbel R, Di Mario C, Bartunek J,
Bonnier J, De Bruyne B, Eberli F R, et al. Temporary scaffolding of
coronary arteries with bioabsorbable magnesium stems: a
prospective, non-randomised multicentre trial. Lancet. 2007 Jun. 2;
369(9576): 1869-75. [0309] 25. Camici G G. What is an optimal
stent? Biological requirements of drug eluting stents.
Kardiovaskulare Medizin. 2008; (11):22-5. [0310] 26. Nishio S,
Kosuga K, Igaki K, Okada M, Kyo E. Long-Term (>10 Years)
Clinical Outcomes of First-in-Human Biodegradable Poly-l-Lactic
Acid Coronary StentaClinical Perspective Igaki-Tamai Stens.
Circulation. 2012; 125(19):2343-53. [0311] 27. NIHR HSC.
Bioresorbable stems for occlusive coronary artery disease.
Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon
Scanning Review. 2012; [0312] 28. Gonzalo N, Macaya C. Absorbable
stent focus on clinical applications and benefits. Vascular health
and risk management. 2012 January; 8:125-32. [0313] 29. Van der
Giessen W J, Lincoff a M, Schwartz R S, Van Beusekom H M. Serruys P
W, Holmes D R, et al. Marked inflammatory sequelae to implantation
of biodegradable and nonbiodegradable polymers in porcine coronary
arteries. Circulation. 1996 Oct. 1; 94(7):1690-7. [0314] 30. Huang
F, Sun L, Zheng J. In vitro and in vivo characterization of a silk
fibroin-coated polyester vascular prosthesis. Artificial organs.
2008 December; 32(12):932-41. [0315] 31. Wang X, Zhang X, Castellot
J, Herman I, Iafrati M, Kaplan D L. Controlled release from
multilayer silk biomaterial coatings to modulate vascular cell
responses. Biomaterials. 2008 March; 29(7):894-903. [0316] 32.
Panilaitis B, Altman G H, Chen J, Jin H-J, Karageorgiou V, Kaplan D
L. Macrophage responses to silk. Biomaterials. 2003 Aug.;
24(18):3079-85. [0317] 33. Lawrence B D, Wharram S, Kluge J a,
Leisk G G, Omenetto F G, Rosenblatt M I, et al. Effect of hydration
on silk film material properties. Macromolecular bioscience. 2010
Apr. 8; 10(4):393-403. [0318] 34. Rockwood D N, Preds R C, Yucel T,
Wang X, Lovett M L, Kaplan D L, Materials fabrication from Bombyx
mori silk fibroin. Nature protocols. 2011 October; 6(10):1612-31.
[0319] 35. Meinel L, Hofmann S, Karageorgiou V, Kirker-Head C,
McCool J, Gronowiez G, et al. The inflammatory responses to silk
films in vitro and in vivo. Biomaterials. 2005 January;
26(2):147-55. [0320] 36. Altman G H, Diaz F, Jakuba C, Calabro T,
Horan R L, Chen J, et al. Silk-based biomaterials. Biomaterials.
2003 February; 24(3):401-16. [0321] 37. Vepari C, Kaplan D L, Silk
as a biomaterial. Progress in polymer science. 2007;
32(8-9):991-1007. [0322] 38. Murphy A R, John P S, Kaplan D L.
Modification of silk fibroin using diazonium coupling chemistry and
the effects on hMSC proliferation and differentiation.
Biomaterials. 2008; 29(19):2829-38. [0323] 39. Murphy A R, Kaplan D
L. Biomedical applications of chemically-modified silk fibroin.
Journal of materials chemistry. 2009 Jun. 23; 19(36):6443-50.
[0324] 40. Sofia S. McCarthy M B, Gronowiez G, Kaplan D L.
Functionalized silk-based biomaterials for bone formation. Journal
of biomedical materials research. 2001 January; 54(1):139-48.
[0325] 41. Ziberman M, Nelson K D, Eberhart R C, Mechanical
properties and in vitro degradation of bioresorbable fibers and
expendable fiber-based stents. Journal of biomedical materials
research. Part B, Applied biomaterials. 2005 August; 74(2):792-9.
[0326] 42. Ramcharitar S, Searuys P W. Fully biodegradable coronary
stems: progress to date. American journal of cardiovascular drugs:
drugs, devices, and other interventions. 2008 January; 8(5):305-14.
[0327] 43. Pritchard E M, Szybala C, Boison D, Kaplan D L. Silk
fibroin encapsulated powder reservoirs for sustained release of
adenosine. Journal of controlled release: official journal of the
Controlled Release Society. 2010 Jun. 1; 144(2):159-67. [0328] 44.
Lu S, Wang X, Lu Q, Hu X, Uppal N, Omenetto F G, et al.
Stabilization of enzymes in silk films. Biomacromolecules. 2009 May
11; 10(5):1032-42. [0329] 45. Lu Q, Wang X, Hu X, Cebe P, Omenetto
F G, Kaplan D L. Stabilization and release of enzymes from silk
finms. Macromolecular bioscience. 2010 Apr. 8; 10(4):359-68. [0330]
46. Zhang W, Wang X, Wang S, Zhao J, Xu L, Zhu C, at al. The use of
injectable sonication-induced silk hydrogel for VEGF(165) and BMP-2
delivery for elevation of the maxillary sinus floor. Biomaterials.
2011 December; 32(35):9415-24. [0331] 47. Saitow C, Kaplan D L,
Castellot J J. Heparin stimulates elastogenesis: application to
silk-based vascular grafts. Matrix biology: journal of the
International Society for Matrix Biology. 2011 June;
30(5-6):346-55. [0332] 48. Wang X, Wenk E, Zhang X, Meinel L,
Vunjak-Novakovic G, Kaplan D L. Growth factor gradients via
microsphere delivery in biopolymer scaffolds for osteochondral
tissue engineering. Journal of controlled release: official journal
of the Controlled Release Society. 2009 Mar. 4; 134(2):81-90.
[0333] 49. Wang X, Week E, Matsumoto A, Meinel L, Li C, Kaplan D L.
Silk microspheres for encapsulation and controlled release. Journal
of controlled release: official journal of the Controlled Release
Society. 2007 Feb. 26; 117(3):360-70.
* * * * *